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Higher levels of testosterone have been associated with fewer anxiety symptoms 
and greater psychological wellbeing. However, additional research is needed to advance 
the clinical use of testosterone in mental healthcare. This dissertation aims to investigate 
the anxiolytic effects of testosterone in men and women through three studies. The first 
study examines the pharmacokinetic profile of a novel testosterone nasal spray, designed 
for the safe and rapid delivery of exogenous testosterone in men and women. The second 
study leverages the utility of this novel spray preparation, and investigates the effect of 
intranasal testosterone on subjective anxiety during a psychosocial challenge. The final 
study extends the anxiolytic effects of exogenous testosterone in women, and explores the 
effect of intranasal testosterone on test anxiety and cognitive performance. Collectively, 
these three studies aim to contribute to a broader understanding of the anxiolytic effects of 
testosterone, and with it, the potential for testosterone to act as a novel pharmaceutical in 
the treatment of anxiety. 
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Chapter 1: Introduction 
There’s no denying it. She is next. Her heart pounding, and breaths quickening with 
looming anticipation. The room is reduced to a blur as she is called to give her presentation. 
She steadies herself against the podium with her sweaty palms as she scans the audience 
for looks of disapproval. Her eyes sunken with dark circles from rehearsing her speech 
repeatedly into the early morning. As she opens her mouth, a new rush of panic spills over 
her as she reads the introductory sentences of her thesis out loud. Suddenly, the room is 
punctured by the sound of applause, signaling the end of her presentation. She walks away 
from the podium in a state of dissociation. She is convinced that she was stuttering and 
making a fool out of herself in front of her esteemed colleagues. She makes a mental note 
to submit an abstract for a poster presentation instead at the next conference. 
Anxiety is a stranger to almost no one. However, for some, feelings of anxiety may 
become so frequent and intense that it is debilitating. The experience of excessive anxiety 
in situations that pose no real threat is the hallmark of a class of mental disorders called 
anxiety disorders. 
DEFINING FEATURES OF ANXIETY DISORDERS 
Nature and Epidemiology 
According to the DSM-5 (American Psychiatric Association, 2013), anxiety 
disorders are a cluster of psychiatric conditions characterized by excessive fear and 
behavioral avoidance. Fear is the emotional response to real or perceived imminent threat, 
whereas anxiety is the anticipation of future threat. Although related, fear is associated with 
surges of autonomic arousal necessary for fight or flight, thoughts of immediate danger, 
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and escape behaviors; whereas anxiety is more often associated with muscle tension and 
vigilance in preparation for future danger and cautious or avoidant behaviors. Although 
recognizing the fear is unrealistic and disproportionate to the actual stimuli (e.g., public 
speaking), anxiety sufferers avoid fear-eliciting situations, or endure them with significant 
distress. Moreover, a DSM-5 diagnosis of anxiety disorder, irrespective of subtype, 
warrants that the anxiety associated with the fear-eliciting situation and related avoidance 
cause significant interference with the normal routine, occupational functioning, or social 
activities, and relationships (American Psychiatric Association, 2013). 
Anxiety disorders have the highest overall prevalence of all psychiatric diagnoses, 
with an estimated 12-month prevalence of 18.1% and a lifetime prevalence of 28.8% 
(Kessler, Berglund, et al., 2005; Kessler, Chiu, Demler, & Walters, 2005). Globally, 273 
million (4.5% of the world’s population) has a diagnosis of anxiety disorder (Vos et al., 
2012), with prevalence and severity twice as high in women than men (McLean, Asnaani, 
Litz, & Hofmann, 2011). 
According to the National Comorbidity Survey Replication, a nationally 
representative face-to-face household survey conducted between 2001 and 2003, the 
median onset for anxiety disorder is approximately 11 years of age (Kessler, Berglund, et 
al., 2005). In a 12-year prospective study, survival analyses revealed an overall chronic 
course for the majority of anxiety disorders (Bruce et al., 2005). Of the different subtypes 
of anxiety disorders, social phobia had the smallest probability of recovery after 12 years 
of follow-up (Bruce et al., 2005). When left untreated, anxiety disorders are unremitting 
illnesses that substantially worsen the quality of life (Olatunji, Cisler, & Tolin, 2007). 
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Psychiatric comorbidity is often observed in those with anxiety disorders. The co-
occurrence of anxiety disorders with other mental, addictive, or physical disorders has 
important implications for treatment and clinical course. According to the Epidemiologic 
Catchment Area study, nearly half (47.2%) of those meeting lifetime criteria for major 
depression also met criteria for a comorbid anxiety disorder (Regier, Rae, Narrow, Kaelber, 
& Schatzberg, 1998). Moreover, individuals with social and simple phobias typically have 
an earlier illness onset, and are more vulnerable to major depression and addictive disorders 
(Regier et al., 1998). The presence of comorbid psychiatric disorders significantly lowered 
the likelihood of recovery from anxiety disorders and increased the probability of their 
recurrence (Bruce et al., 2005). 
Indirect and Direct Costs of Illness 
Anxiety disorders are associated with significant impairment. Even after 
controlling for comorbidity and sociodemographic factors, baseline presence of any 
anxiety disorder is significantly associated with suicidal ideation and suicide attempts in 
both cross sectional and longitudinal analysis (Khan, Leventhal, Khan, & Brown, 2002; 
Nepon, Belik, Bolton, & Sareen, 2010; Sareen et al., 2005). Moreover, compared to non-
anxious controls, individual with anxiety disorders report greater impairments in general 
health (Gater et al., 1998; Ormel et al., 1994; Simon, Ormel, VonKorff, & Barlow, 1995), 
family relationships (Lochner et al., 2003; Rapaport, Clary, Fayyad, & Endicott, 2005), 
marriage or romantic relationships (Aderka et al., 2012; Davila & Beck, 2002; Eng, 
Heimberg, Hart, Schneier, & Liebowitz, 2001), social network (Barrera & Norton, 2009; 
Lochner et al., 2003; Rapaport et al., 2005; Wittchen, 2002), and occupational functioning 
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(Goetzel et al., 2004; Lim, Sanderson, & Andrews, 2000; Turner, Beidel, Dancu, & Keys, 
1986).  
Given the adverse effects associated with anxiety disorders, it is not surprising that 
they are linked to increased use of medical services. Compared with individuals diagnosed 
with other psychiatric disorders, patients with anxiety disorders are high care utilizers who 
present to general practitioners more frequently than to psychiatric professionals 
(Marciniak et al., 2005). 
The staggering costs associated with anxiety disorders have been well documented. 
In 1990, the estimated annual cost of anxiety disorders was approximately $42.3 billion in 
the United States alone (Greenberg et al., 1999), a figure which accounted for 31.5% of all 
mental health expenditures that year (DuPont et al., 1996). Although a more recent cost 
estimate of anxiety disorders in the United States has yet to be published, the World Health 
Organization approximated the global cost of all mental health expenditures as $2.5 trillion 
in 2010, and projected this value to increase to $6.0 trillion by 2030 (Bloom et al., 2011). 
Using retrospective, multivariate analyses while controlling for demographic 
characteristics, medical comorbidities, anxiety diagnosis, and prior resource utilization, a 
smearing estimate was used to calculate the total medical costs for patients with any anxiety 
disorder (Marciniak et al., 2005). Findings show that the mean estimated total medical cost 
for individuals diagnosed with any anxiety disorder was $6,475 in 2005 (Marciniak et al., 
2005); taking into account inflation, this value increases to $8,427.84 in 2019. 
In summary, anxiety disorders are associated with impaired qualify of life, 
increased risk for comorbidity, and significant financial cost. 
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ETIOLOGY OF ANXIETY DISORDERS 
Learning Theory 
The modern learning theory of anxiety disorders stems from the pioneering work 
of Watson and Rayner (1920). In particular, their research on the acquisition of fears and 
phobias with Little Albert. Watson and Rayner (1920) argued that phobias are simply 
intense classically conditioned fears that develop when a neutral stimulus is paired with a 
traumatic event, such as when their Little Albert acquired an intense fear of rats (and likely 
Watson himself), after hearing a frightening gong paired with the presence of a rat. Indeed, 
across numerous studies using retrospective recall, research has found that people with 
specific phobias can recall a traumatic conditioning event when their phobia began (Öst & 
Hugdahl, 1981).  
Aside from concerns associated with recall bias in research on early learning 
histories, another criticism of early conditioning theory centered on the observation that 
many people with phobias do not appear to have had any relevant history of classical 
conditioning (Rachman, 1984). One explanation for this apparent discrepancy is the 
speculation that simply observing others experiencing a trauma or behaving fearfully can 
be sufficient for fears or phobias to develop. The strongest experimental evidence in 
support of vicarious conditioning stems from a series of primate studies showing that strong 
and persistent fears can be learned through observation alone (Cook, Mineka, Wolkenstein, 
& Laitsch, 1985). When laboratory-reared young adult rhesus monkeys, who, initially, 
were not afraid of snakes, watched unrelated, wild-reared monkeys reacting very fearfully 
in the presence of live and toy snakes, they showed a rapid acquisition of an intense fear 
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of snakes that did not diminish over a three-month period (Cook et al., 1985). Extending 
beyond simple phobias, vicarious conditioning may also develop in social anxiety (e.g., 
observing another being ridiculed or humiliated in a social situation; Mineka & Zinbarg, 
2006). Öst and Hugdahl (1981) found that 13% of individuals with social anxiety recalled 
vicarious learning experiences as having played a role in the origins of their anxiety.  
Taken together, research suggests that in addition to direct conditioning, fears may 
also be acquired through vicarious conditioning. It should be noted, however, that theories 
of early direct-conditioning and early vicarious-conditioning are susceptible to bias 
associated with retrospective recall, thus weakening subsequent causal inferences. 
Cognitive Theory 
Contemporary cognitive theory of anxiety disorders has its origins in three lines of 
theory and research. The first is Albert Ellis’s (1973) influential work on rational 
psychotherapy, later called rational-emotive behavior therapy. This theory posited that 
emotional dysfunction is the consequence of irrational beliefs. Similarly, Beck, Emery, and 
Greenberg (1985) suggested that anxiety disorders develop in response to faulty threat 
appraisals, which are the result of threat-related schemas. Lastly, cognitive theories of 
anxiety disorders have also been heavily influenced by basic cognitive psychology 
investigations into information processing in healthy individuals.  
From a cognitive perspective, excessive fear and anxiety are consequences of 
exaggerated threat appraisals to neutral or innocuous situations. According to Beck et al. 
(1985), these appraisals are experienced as negative automatic thoughts in response to 
situations that are of relevance to the individual with an anxiety disorder. For example, 
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someone with social anxiety may have an automatic thought of “they think I’m stupid” in 
a public speaking scenario. According to cognitive theories, individuals with anxiety 
disorders overestimate the probability and cost of harm. In addition, they show biased 
safety estimates and underestimate their own ability to cope with harm (Beck et al., 1985; 
Salkovskis, 1996).  
It is noteworthy that threat appraisals in anxiety disorders are not only related to 
external stimuli, but may also concern symptoms of anxiety, such as in individuals with 
generalized anxiety disorder, who perceive their own worrying as threatening (Wells & 
Carter, 2001). Threat appraisals may also extend to bodily sensations, such as in individuals 
with panic disorder, in which the catastrophic appraisal of bodily sensations lies at the core 
of the disorder (Clark, 1986).  
According to Beck’s cognitive model, the threat appraisals of individuals with 
anxiety disorder(s) are thought to be influenced by maladaptive cognitive schemas, or 
underlying cognitive structures that have developed in response to earlier experiences 
(Beck et al., 1985). It is thought that these negative schemas lead to biased automatic 
processing when they are activated (Beck et al., 1985), resulting in greater salience of 
threat-related information relative to safety-related information. It is believed that through 
this process, maladaptive schemas are maintained over time. 
Behavioral Genetics 
Family and twin studies have found that panic disorder, generalized anxiety 
disorder, and phobias aggregate in families and demonstrate significant heritability 
(Hettema, Neale, & Kendler, 2001). This is supported by large-scale twin studies of panic 
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disorder (Kendler, Neale, Kessler, Heath, & Eaves, 1993; Scherrer et al., 2000), 
generalized anxiety disorder (Hettema, Prescott, & Kendler, 2001; Scherrer et al., 2000), 
and specific phobias (Carey & Gottesman, 1981). Estimated heritabilities across the 
disorders are modest, ranging from 30% - 40%, which are significantly lower compared to 
disorders such as schizophrenia and bipolar disorder (Hettema, Neale, et al., 2001). These 
findings suggest that a significant portion of the variance in liability is explained by 
environmental factors.  
Because most large scale family and twin studies limit analyses to anxiety 
disorders, the association between anxiety symptomatology seen in individuals with 
subclinical symptoms compared to those diagnosed with an anxiety disorder is unclear 
(Hettema, Neale, et al., 2001). However, if symptoms and disorders are considered on the 
same continuum of increased severity and duration, twin studies have indeed found genetic 
contributions to nonspecific anxiety symptoms (Jardine, Martin, Henderson, & Rao, 1984), 
fears (Kendler, Karkowski, & Prescott, 1999; Kendler, Neale, Kessler, Heath, & Eaves, 
1992; Neale et al., 1994; Torgersen, 1979), and phobia (Kendler et al., 1995). 
Finally, despite nearly two times greater prevalence rate in women compared to 
men, the same underlying liability structure broadly account for patterns of comorbidity 
among anxiety disorders, suggesting that risk factors are independent of sex (Hettema, 
Prescott, Myers, Neale, & Kendler, 2005). 
Neurocircuitry 
Progress in the development of neurocircuitry models of anxiety disorders was 
made possible by major developments in the field of neuroimaging. Many of the early 
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neuroimaging studies were based on preclinical models of stress and conditioned fear 
(Davis, 1992; LeDoux, Iwata, Cicchetti, & Reis, 1988). Through the elegant work of these 
and other researchers, a basic model of normal fear responding was developed and refined, 
leading to the description of a “fear neurocircuitry” centered around the amygdala 
(LeDoux, Cicchetti, Xagoraris, & Romanski, 1990). Since then, the structure, function, and 
activity of the amygdala have served as the basis for most contemporary human 
neurocircuitry models of anxiety.  
Located in the anterior part of the medial temporal lobe, the amygdala has been 
established as the central node for the coordination of autonomic and behavioral fear 
responding (LeDoux et al., 1990). Sensory information critical to threat assessment is 
processed via pathways running through the anterior thalamus to the amygdala (LeDoux et 
al., 1988). In preparation for action in response to threat, the amygdala activates ascending 
projections to motor areas and descending projections to brain stem nuclei that control 
autonomic responses and arousal (Kent & Rauch, 2003). The amygdala also facilitates the 
acquisition of additional information regarding specific threats via reciprocal projections 
to subcortical and limbic cortical regions (LeDoux, 1996). Critical feedback to the 
amygdala is provided by specific brain regions, including the medial frontal cortex and 
cortico-striato-thalamic circuits, which mediate “gating” at the level of the thalamus, 
thereby regulating the flow of incoming information that reaches the amygdala (Kent & 
Rauch, 2003). The medial frontal cortex, including anterior cingulate and medial and 
orbitofrontal cortex, provides critical “top-down” governance over the amygdala, curbing 
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the fear response once danger has passed or when a potentially threatening stimulus has 
changed (Kent & Rauch, 2003).  
Convergent neuroimaging data are consistent with the notion of exaggerated 
amygdala activation in response to emotionally-provocative stimuli, in a number of anxiety 
disorders (Kent & Rauch, 2003; Shin & Liberzon, 2010). Facial expressions have been 
especially effective probes of amygdala responses in social anxiety, consistent with 
hypersensitivity in a specialized system for assessing a specific class of potentially 
threating stimuli (Birbaumer et al., 1998; Schneider et al., 1999). Data regarding amygdala 
function in panic disorder and generalized anxiety disorder are limited, and thus overall are 
inconclusive (Shin & Liberzon, 2010). One potential conceptualization of these findings is 
that amygdala hyperactivation is a common pathway for exaggerated fear in response to 
specific emotional stimuli (Shin & Liberzon, 2010). Thus, anxiety disorders characterized 
by specific identifiable stimuli (e.g., social anxiety and specific phobia) will result in 
exaggerated amygdala reactivity following exposure to the feared stimulus. Panic attacks, 
on the other hand, can occur in the absence of such stimuli (i.e., “out of the blue”) and may 
involve activation of other structures within the fear/anxiety neurocircuitry. In line with 
this hypothesis, neuroimaging research has raised a wide range of possible neural substrates 
underlying panic disorder. Specifically, regional abnormalities within the temporal lobe 
may reflect fundamental deficits in threat assessment in panic disorder (Fontaine, Breton, 
Déry, Fontaine, & Elie, 1990; Vythilingam et al., 2000). In particular, abnormalities in the 
parahippocampal gyrus have been identified in panic disorder (Massana et al., 2003).  
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In addition to the amygdala, research has also reported exaggerated insular cortex 
activation in specific phobia versus healthy controls in response to phobia- or fear-related 
pictures, videos, and words (Dilger et al., 2003; Goossens, Schruers, Peeters, Griez, & 
Sunaert, 2007; Schienle, Schäfer, Walter, Stark, & Vaitl, 2005; Straube, Mentzel, Glauer, 
& Miltner, 2004). In addition, treatment studies have reported decreased insula activation 
following cognitive behavioral treatment (Goossens, Sunaert, Peeters, Griez, & Schruers, 
2007; Straube, Glauer, Dilger, Mentzel, & Miltner, 2006). 
Although the literature presently is small, it appears that the medial prefrontal 
cortex may be elevated in generalized anxiety disorder. Activations in the dorsal anterior 
cingulate cortex (dACC) and rostral anterior cingulate cortex (rACC) appear to be elevated 
in response to fearful facial expressions in adolescents with generalized anxiety disorder 
(McClure et al., 2007). Moreover, in a mixed cohort of subjects with generalized anxiety 
and social anxiety, those with higher intolerance for uncertainty had elevated rACC and 
subgenual ACC activation during a decision-making task (Krain et al., 2008). 
Taken together, anxiety disorders are associated with hyperactivation in emotion-
generating regions, and hypoactivation in prefrontal/regulatory regions. Interestingly, 
evidence of differential patterns is also emerging, such that greater involvement of 
emotion-generating regions is reported in panic disorder and specific phobia, and greater 
involvement of prefrontal regions is reported in generalized anxiety disorder (Duval, 
Javanbakht, & Liberzon, 2015; Sylvester et al., 2012). 
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Psychoneuroendocrinology 
Advances in diagnosis and treatment have led to renewed interest in the 
pathophysiology of anxiety symptoms and disorders, particularly in understanding 
pervasive sex differences in prevalence rates among men and women. A growing body of 
literature has focused on the role of gonadal hormones such as testosterone in the 
development and maintenance of anxiety (e.g., Fernández-Guasti, Fiedler, Herrera, & 
Handa, 2012; Goel & Bale, 2008, 2009; Maeng & Milad, 2015; McHenry, Carrier, Hull, 
& Kabbaj, 2014; Mueller, Grissom, & Dohanich, 2014; Palanza, 2001). Testosterone, the 
end product of the hypothalamic-pituitary-gonadal axis, is primarily secreted in the testes 
of males, and the ovaries of females. On average, testosterone levels are about 7 to 8 times 
greater in men as they are in women (Torjesen & Sandnes, 2004).  
Women are more likely to experience symptoms of anxiety and depression during 
periods of marked hormonal fluctuations, such as puberty, postpartum, and perimenopause 
(Douma, Husband, O’donnell, Barwin, & Woodend, 2005). Beginning in puberty, gonadal 
hormones estrogen and progesterone in females, and testosterone in males, begin to surge. 
In male rats, prepubertal castration is associated with anxiogenic effect of a novel 
environment, as evidenced by reduced activity in open field tests (Brand & Slob, 1988), 
and behavioral inhibition among interaction with other male rats (Primus & Kellogg, 
1990). Relatedly, proestrous (i.e., high levels of 17-β estradiol) female rats and mice show 
decreased activity and behavioral inhibition, indicating increased anxiety-like behaviors 
(Díaz-Véliz, Butrón, Benavides, Dussaubat, & Mora, 2000; Diaz-Veliz, Soto, Dussaubat, 
& Mora, 1989; Mora, Dussaubat, & Díaz-Véliz, 1996; Morgan & Pfaff, 2002; Paré & 
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Redei, 1993). In humans, earlier pubertal timing is linked to higher reported anxiety 
symptoms in girls, but not boys (Deardorff et al., 2007; Reardon, Leen-Feldner, & 
Hayward, 2009). One explanation for this set of findings is the interaction between gonadal 
and stress hormones predisposing females to stress-related diseases such as anxiety and 
depression (Solomon & Herman, 2009). Depression and anxiety are both associated with 
aberrant secretion of glucocorticoids (Burke, Davis, Otte, & Mohr, 2005; Vreeburg et al., 
2010). The hypothalamic-pituitary-gonadal axis has been shown to modulate the 
deleterious effects of glucocorticoids by suppressing the hypothalamic-pituitary-adrenal 
axis (Solomon & Herman, 2009). In fact, the anxiolytic effects of testosterone have been 
shown in both animals and humans in response to stress. 
Anxiolytic Effects of Testosterone in Animals 
In animals, anxiety-like behaviors are assessed based on the animal’s willingness 
to explore a novel environment as opposed to avoiding open exposure (reviewed in Nestler 
& Hyman, 2010). Several effects of testosterone have been observed in measures of 
anxiety-like behavior in adult male rodents. Gonadectomy in adult male rodents results in 
increased anxiety-like behaviors in a battery of behavioral tests, such as the elevated plus 
maze, open field test, and defensive probe-burying, compared to sham-operated controls 
(Adler, Vescovo, Robinson, & Kritzer, 1999; Fernández-Guasti & Martínez-Mota, 2003; 
Frye & Seliga, 2001; Morsink et al., 2007; Slob, Bogers, & van Stolk, 1981). These effects 
were reversed by testosterone replacement (Adler et al., 1999; Fernández-Guasti & 
Martínez-Mota, 2005; Frye & Seliga, 2001; Slob et al., 1981). Moreover, testosterone 
replacements were equally as effective as the administration of typical tricyclic 
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antidepressant imipramine in alleviating anxiety-like behaviors induced by two-weeks of 
chronic social isolation (Carrier & Kabbaj, 2012). Similarly, testosterone administration in 
intact adult male rodents reduced anxiety-like behavior in the elevated plus maze, open 
field test, and light-dark box test, compared to vehicle-treated controls (Bitran, Kellogg, & 
Hilvers, 1993; Frye, Edinger, & Sumida, 2008). 
In intact female rodents, injections of testosterone reduced anxiety-like behavior in 
the open field test and elevated plus maze, compared to vehicle treated controls (Frye & 
Lacey, 2001). Similarly, testosterone administration in intact female rodents also decreased 
anxiety-like behavior in a defensive burying task through an androgen-mediated effect, 
compared to vehicle treated controls (Gutiérrez-García, Contreras, Vásquez-Hernández, 
Molina-Jiménez, & Jacome-Jacome, 2009). 
Anxiolytic Effects of Testosterone in Humans 
The association between testosterone levels and anxiety symptoms in humans is 
evident in males with hypogonadism, a condition in which reduced functional activity of 
the gonads results in decreased levels of testosterone. Hypogonadal men exhibit 
significantly higher prevalence of anxiety disorders compared to those with androgens 
within the normative range (Aydogan et al., 2012; Lašaitė, Čeponis, Preikša, & Žilaitienė, 
2014). Similarly, men treated with androgen-depleting drugs exhibit lower mood (Schmidt 
et al., 2004), and greater likelihood of developing an anxiety disorder (DiBlasio et al., 
2008). In men with social anxiety, defeat following competition is associated with a 
significant drop in testosterone, an effect not observed in non-anxious men (Maner, Miller, 
Schmidt, & Eckel, 2008). In healthy adolescent males, declines in salivary testosterone due 
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to circadian flux is correlated with an increase in anxiety-like measures (Granger et al., 
2003). 
Although studies of testosterone administration in women are limited, existing 
evidence supports an anxiolytic effect of testosterone. Compared to placebo-treated 
controls, administration of testosterone resulted in diminished preconscious selective 
attention to threatening stimuli (van Honk, Peper, & Schutter, 2005), reduced gaze 
avoidance in individuals with social anxiety disorder (Enter, Terburg, Harrewijn, 
Spinhoven, & Roelofs, 2016), reduced fear-potentiated startle response (Hermans, Putman, 
Baas, Koppeschaar, & van Honk, 2006), and increased behavioral approach (Enter, 
Spinhoven, & Roelofs, 2014, 2016). Further, transdermal application of testosterone in 
women experiencing age-related declines in androgens resulted in substantially improved 
mood and psychological well-being, compared to placebo treated individuals (Goldstat, 
Briganti, Tran, Wolfe, & Davis, 2003). Compared to healthy controls, women with anxiety 
disorders, including generalized anxiety, social phobia, and agoraphobia express lower 
levels of salivary testosterone (Giltay et al., 2012). 
Effects of Testosterone on Neurocircuitry Implicated in Anxiety 
In humans, anxiety disorders are associated with both structural and functional 
abnormalities within the amygdala, hippocampus, and prefrontal cortex (Shin & Liberzon, 
2010), three brain regions which appear to be strongly influenced by testosterone 
(McHenry et al., 2014). In animal models, more discrete sub-regions of these general brain 
sites have been implicated in anxiety-like behaviors (reviewed in Singewald, 2007). 
Collectively, testosterone exerts its anxiolytic effects in both humans and animals through 
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the down regulation of the amygdala (Bingham & Viau, 2008; Hermans et al., 2007; 
Linfoot et al., 2009; Radke et al., 2015; Stanton, Wirth, Waugh, & Schultheiss, 2009; van 
Wingen, Mattern, Verkes, Buitelaar, & Fernández, 2010), up regulation of the prefrontal 
cortex (Schutter & van Honk, 2004; Sladky et al., 2015; van Wingen et al., 2010; Volman, 
Toni, Verhagen, & Roelofs, 2011), and increased cell proliferation in the hippocampus by 
dampening the neurotoxic effects of glucocorticoids (Hermans et al., 2007; Rubinow et al., 
2005; Viau, 2002). 
Amygdala. The amygdala plays a major role in anxiety and fear responses in 
humans and rodents (reviewed in Ressler, 2010). Although human imaging studies 
examining potential brain regions involved in the effects of testosterone on anxiety are 
extremely limited, existing findings demonstrate sexually divergent associations between 
testosterone and amygdala activation. Specifically, greater levels of testosterone is 
associated with increased amygdala activation in men (Derntl et al., 2009), but not in 
women (Stanton et al., 2009). 
In male neonatal rodents, gonadectomy is associated with fewer androgen-receptor-
containing cells in the medial amygdala in adulthood, compared with sham operated 
controls; an effect that was reversed by testosterone administration 1-5 days during the 
postnasal period, but not in adulthood (Bingham & Viau, 2008). Further, defensive burying 
was associated with expression of androgen receptors in the medial amygdala (Linfoot et 
al., 2009). 
Across a series of studies, injection of a 5α-reductase inhibitor (a class of drugs 
with anti-androgen effects) into the amygdala of intact female rodents increased anxiety-
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like behavior in the open field test, elevated plus maze, and defensive freezing tests, 
compared to vehicle-treated controls (Walf, Sumida, & Frye, 2006). Aromatization of 
testosterone to estradiol may also have anxiolytic effects within the amygdala. Injection of 
estradiol into the amygdala of ovariectomized female rats decreased anxiety-like behavior 
in the open field, elevated plus maze, and hot plate tasks, compared to sham-operated 
controls (Frye & Walf, 2004).  
Hippocampus. The hippocampus has been extensively documented as a critical site 
in anxiety disorders (McHenry et al., 2014). Preclinical evidence suggests that testosterone 
acting on the hippocampus has a number of anxiolytic and protective cellular actions. Some 
of the protective effects of testosterone in the hippocampus may be due to its ability to 
reduce the aversive effects of glucocorticoids in response to stress (Hermans et al., 2007; 
Rubinow et al., 2005; Viau, 2002), and facilitate molecular mechanisms that favor cell 
proliferation, growth, and survival (McHenry et al., 2014). 
The protective effects of testosterone on the hippocampus can be seen during both 
organizational and activational periods in rodent models. Perinatal androgen treatment 
increases neuronal soma size, dendritic length and branching, and also the volume of the 
CA3 pyramidal cell layer and the entire CA3 region of the hippocampus (Isgor & 
Sengelaub, 1998, 2003). Further, neonatal gonadectomy decreased hippocampal spine 
density in adulthood, an effect reversed with testosterone treatment (J. L. Dawson, Cheung, 
& Lau, 1975). Similarly, gonadectomy in adulthood is associated with cellular oxidative 
damage and morphological alterations in the hippocampus, an effect that was improved 
following testosterone administration, compared to vehicle treatment (Meydan et al., 
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2010). In intact female rodents, testosterone administration following adrenalectomy 
decreased the number of pyknotic cells undergoing cell death in the hippocampus, 
compared to control-treated females (Frye & McCormick, 2000). 
Prefrontal cortex. Neuroimaging studies in humans suggest the anxiolytic effects 
of testosterone may be the result of its influence on the cortical connectivity between the 
prefrontal cortex and subcortical regions (e.g., amygdala), particularly in the modulation 
of approach and avoidance behaviors (Volman et al., 2011). In a sample of age matched 
male participants, a negative feedback loop is observed between the orbitofrontal cortex 
and amygdala in healthy controls, compared to a positive, excitatory connection in patients 
with social anxiety (Sladky et al., 2015).  
Exogenous studies in healthy females show that testosterone administration rapidly 
reduced functional coupling of the amygdala with the orbitofrontal cortex, and enhanced 
amygdala coupling with the thalamus (van Wingen et al., 2010). Similarly, testosterone 
administration is associated with significant increase in delta power in the midfrontal 
region of the brain (Schutter & van Honk, 2004). These findings suggest that the anxiolytic 
effects of testosterone may be the result of increased top-down, regulatory control of the 
amygdala from the prefrontal cortex. 
Taken together, clinical and preclinical evidence in humans and rodents suggests 
an anxiolytic effect of testosterone. Considering pervasive sex differences in the prevalence 
of anxiety disorders (Kessler, Chiu, et al., 2005), investigation of testosterone’s therapeutic 
effects has the potential to improve mental health in both men and women worldwide.  
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OVERVIEW OF PROPOSED STUDIES 
This dissertation includes three experiments, that, taken together, describe a 
multipronged investigation of the anxiolytic effects of testosterone in men and women. The 
first study examines the pharmacokinetic profile of a novel testosterone nasal spray, 
designed for the safe and rapid delivery of exogenous testosterone in men and women. The 
second study leverages the utility of this novel spray preparation, and investigates the effect 
of intranasal testosterone on subjective anxiety during a psychosocial challenge. The final 
study extends the anxiolytic effects of exogenous testosterone in women, and explores the 
effect of intranasal testosterone on cognitive performance. Collectively, these three studies 
aim to contribute to a broader understanding of the anxiolytic effects of testosterone, and 
with it, the potential for testosterone to act as a novel pharmaceutical in the treatment of 
anxiety. 
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Chapter 2: Pharmacokinetics of Intranasal Testosterone Spray 
ABSTRACT 
Despite various existing methods of exogenous testosterone administration, 
currently none are ideal for psychological research purposes. The aim of the present study 
is to examine the pharmacokinetic profile of a novel intranasal testosterone spray in both 
healthy men and women. Twenty participants (35% female) contributed pharmacokinetic 
data by self-administering 14 mg of testosterone via intranasal spray, and providing blood 
serum samples at baseline (pre-administration), 15, 30, and 60 minutes after spray 
administration. Results indicate that total and free testosterone concentrations increased in 
a monotonic fashion at 15- and 30-minutes post testosterone administration, peaking at 30 
minutes (242.0% and 2653.6% increases in total testosterone from baseline for men and 
women, respectively), and declining 60 minutes following administration. This study 
establishes the pharmacokinetic profile of a novel intranasal testosterone delivery system 
and provides evidence for the effectiveness and utility of intranasally-delivered 
testosterone in both healthy men and women. 
BACKGROUND 
Limitations of Existing Exogenous Testosterone Administration Modalities 
Despite numerous established modes of exogenous testosterone administration, 
currently none are ideal for psychological research purposes. Testosterone injections are 
invasive and results in wide fluctuations in circulating levels, making rigorous 
experimental control difficult to establish (Nieschlag, 2006). Testosterone patches are 
associated with high rate of skin irritation at the site of administration (Tenover, 2003), 
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thus possibly confounding subsequent behavioral outcomes. Oral administration of 
testosterone must be coupled with a high fat meal, thereby making experimental designs 
unnecessarily complex; and even then, they typically yield low absorption rates (Haren, 
Chapman, Coates, Morley, & Wittert, 2005; Wittert et al., 2003). Testosterone gels, while 
one of the most widely accepted modes of exogenous testosterone administration, poses 
significant likelihood of skin-to-skin transfer, which drastically increases risk of 
unintended contamination (Kunz, Klein, Clemons, Gottschalk, & Jones, 2004; Swerdloff 
et al., 2000). Following standard topical gel application, up to 60% of testosterone remains 
on unwashed skin eight hours after use (de Ronde, 2008). Despite this and similar findings 
(e.g., Kathiresan, Carr, & Attia, 2011; Mazer et al., 2005; Merhi & Santoro, 2007), initial 
studies with gel applications minimized concerns that meaningful transfer could occur even 
after intense skin-to-skin contact (Rolf, Knie, Lemmnitz, & Nieschlag, 2002). Instead, they 
suggested that the rapid evaporation of alcohols left the residual testosterone crystallized 
and inert (Cabrera & Rogol, 2013). These studies likely underestimated the heightened 
androgen sensitivity of pre-pubertal children and women. More recent studies in untreated 
women showed significant increases in total serum testosterone from baseline following 
contact with a man two hours after application of a 1.62% testosterone gel (Stahlman et al., 
2012b, 2012a). 
Although rare, the consequences of unintended contamination in children and 
women can be devastating. Potential consequences include virilization of young girls and 
boys (the development of male physical characteristics in a female or precociously in a 
boy), heightened sexuality, and aggressive behavior (Bhowmick, Ricke, & Rettig, 2007; 
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Brachet, Vermeulen, & Heinrichs, 2005; Cavender & Fairall, 2011; Kathiresan et al., 2011; 
Kunz et al., 2004; Merhi & Santoro, 2007; Yu, Punyasavatsu, Elder, & D’Ercole, 1999). 
Moreover, premature virilization carries negative psychosocial effects that extend beyond 
childhood; and long-term exposure of androgens accelerates skeletal maturation, an 
irreversible outcome that can truncate adult height (Cabrera & Rogol, 2013). Additionally, 
clitoromegaly and penile enlargement may not be completely reversible once exposure to 
the androgen ceases (Kathiresan et al., 2011; Merhi & Santoro, 2007). In May 2009, the 
United States Food and Drug Administration (FDA) imposed a black-box warning on two 
testosterone gels after investigating eight reports of children nine months to five years old 
who showed signs of virilization after being exposed to adults who used the products, 
AndroGel 1% and Testim 1% (Brachet et al., 2005; Kunz et al., 2004; Lakshman & Basaria, 
2009; Miller, Rogol, & ZumBrunnen, 2012). Despite these black-box warnings, which are 
the highest of their kind, instances of unintentional secondary exposure continue to be 
reported (Cabrera & Rogol, 2013). In fact, more than a dozen additional cases of children 
who developed complications due to unintended contamination are currently under FDA 
review.  
Taken together, these data point to a critical need for safer and more efficacious 
route of testosterone administration in men and women that minimizes potential risk to 
others. 
Intranasal Drug Administration 
Intranasal administration represents a viable option for local and systemic delivery 
of diverse therapeutic compounds (Behl, Pimplaskar, Sileno, & Romeo, 1998; Costantino, 
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Sileno, & Johnson, 2005; Illum, 2000, 2003; Song, Wang, Thakur, Meidan, & Michniak, 
2004), and has been reported to effectively bypass the blood-brain barrier in mice, rats, 
primates, and humans (De et al., 2005; Deadwyler, Porrino, Siegel, & Hampson, 2007; 
Reger et al., 2006; Ross et al., 2004; Thorne, Hanson, Ross, Tung, & Frey, 2008). Intranasal 
targeting of drugs to the central nervous system avoids hepatic first pass metabolism, which 
allows for a lower therapeutic dose and fewer systematic side effects (Johnson, Hanson, & 
Frey, 2010); all of which may maximize convenience, comfort, and compliance associated 
with drug administration (Banks, Morley, Niehoff, & Mattern, 2009; Costantino, Illum, 
Brandt, Johnson, & Quay, 2007; Mattern, Hoffmann, Morley, & Badiu, 2008). Compared 
to other administration methods, intranasal delivery is non-invasive, painless, does not 
require sterile preparation, minimizes possible contamination, and is easily and readily 
administered by the individual (Costantino et al., 2007). 
There are three routes of delivery from the nasal cavity to the central nervous 
system (Ross et al., 2004; Thorne et al., 2008; Thorne, Pronk, Padmanabhan, & Frey, 
2004): 
Olfactory Pathway 
Once therapeutic compounds are administered through the nasal cavity, they travel 
to the olfactory mucosa, which contains olfactory receptor neurons that are responsible for 
transduction (Selvaraj, Gowthamarajan, & Karri, 2017). Molecules reach the olfactory 
receptor neurons by paracellular or transcellular mechanism, and cross the cribriform plate 
to reach the olfactory bulb located on the surface of the brain (Thorne et al., 2004). From 
the olfactory nerves, the therapeutic compounds then enter the cerebrospinal fluid and are 
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distributed throughout the brain. Following nasal administration, only few minutes is 
required for compounds to reach specific brain regions (i.e., cortex, cerebrum, and 
cerebellum) via olfactory transport. 
Trigeminal Pathway 
Testosterone molecules may also enter the brain through the trigeminal pathway. 
Once compounds diffuse through the mucosa of the nasal cavity, it reaches the ophthalmic 
branch of the trigeminal nerve, which innervates the dorsal part of the nasal mucosa. 
Therapeutic compounds transport through the trigeminal nerve pathway via intracellular 
transport (axonal transport) or endocytosis (Johnson et al., 2010), passing through the 
cribriform plate to reach the forebrain. 
Systemic Pathway 
Drug uptake into the brain from nasal cavity also occurs through blood circulation. 
Due to the rich vasculature of the respiratory epithelium, both small and large molecules 
are absorbed into blood circulation and are transported to the brain by bypassing the blood 
brain barrier (Banks, 2012; Banks et al., 2009). Lipophilic molecules such as testosterone 
easily crosses the blood brain barrier, and is then transferred to the carotid arterial blood 
supply to the brain and spinal cord, through a processed called counter current exchange 
(Selvaraj et al., 2017). Compared to olfactory and trigeminal pathways, the systemic 
pathway of drug delivery may take upwards of 20-30 minutes (Upadhyay, 2014). 
Pharmacokinetic Profiles of Intranasal Testosterone Gel 
Several studies have established the pharmacokinetic profiles of intranasal 
testosterone gel administration (Mattern et al., 2008; Rogol, Tkachenko, & Bryson, 2016). 
 25 
In a study with eight hypogonadal men, a single dose of 7.6 mg of intranasal testosterone 
gel led to rapid absorption and peak total testosterone concentrations 1.08 hours (SD 0.71) 
following administration, resulting in a 341.9% increase of total testosterone from mean 
baseline concentration of 130.8 ng/dL (SD 87.4 ng/dL) to mean peak concentration of 578 
ng/dL (SD 234 ng/dL) (Mattern et al., 2008).  
When the dose is doubled to 15.2 mg, mean total testosterone concentration peaked 
at 804 ng/dL (SD 315 ng/dL) 1.40 hours (SD 0.94) following administration, resulting in 
514.6% overall increase from baseline (Mattern et al., 2008). When the dose is tripled to 
22.8 mg, it did not yield significantly larger total testosterone concentrations compared to 
dose of 15.2 mg. Here, the mean total testosterone concentration peaked at 842 ng/dL (SD 
431 ng/dL) 1.02 hours (SD 0.68) following administration, resulting in 543.7% overall 
increase from baseline (Mattern et al., 2008).  
Similarly, Acerus Pharmaceuticals Corporation (Mississauga, ON Canada), 
developed another intranasal testosterone gel (Natesto™) for the treatment of male 
hypogonadism (Rogol et al., 2016). A single pump of Natesto™ from a non-pressurized, 
manual pump dispenser administers 5.5 mg testosterone through a nasal applicator directly 
into the mucosa of the nasal vestibule of each nostril, resulting in 11 mg of testosterone in 
total to be absorbed into the blood stream (Rogol et al., 2016).  
In a sample of 306 hypogonadal men (Mage = 54.4, SDage =10.9), a single dose of 
5.5 mg of Natesto™ intranasal gel led to peak total testosterone concentrations 1.4 hours 
(SD 2.5) following administration, resulting in a 461.3% increase in total testosterone from 
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mean baseline concentration of 186.3 ng/dL (SD 92.6) to mean peak concentration of 
1045.7 ng/dL (SD 467.1) (Rogol et al., 2016). 
Present Study 
Although existing intranasal testosterone gel applications are promising, time to 
peak concentrations and the speed of uptake might be improved by using a more aqueous 
form of testosterone, such as in the form of an intranasal spray. Moreover, existing studies 
typically employ hypogonadal men as research participants, making it difficult to 
generalize pharmacokinetic data to healthy young men and women typically employed in 
psychological research studies. Thus, the aim of the present study is to examine the 
pharmacokinetic profile of an intranasal testosterone spray in both healthy, eugonadal men 
and women. 
METHODS 
Testosterone Spray Formulation 
An intranasal testosterone spray was developed for the purpose of this study in 
collaboration with a local compounding pharmacy. The testosterone nasal spray used in 
this study contains 1% synthetic ester of testosterone (testosterone propionate), combined 
with non-active ingredients including purified water, polyoxyethylated castor oil, medium 
chain triglycerides, and polycarbophil. Based on values obtained in previous studies using 
intranasal testosterone (Mattern et al., 2008; Rogol et al., 2016), where doses of 11 mg and 
15.2 mg yielded peak total testosterone concentrations (and greater doses did not yield 
significantly higher total testosterone concentrations), 14 mg of testosterone is 
administered via intranasal spray. Individuals familiar with AndroGel® (Unimed 
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Pharmaceuticals, Inc., Deerfield, IL) may find this dose to be extremely low given that the 
average dose is 150 mg for transdermal testosterone (Eisenegger, von Eckardstein, Fehr, 
& von Eckardstein, 2013; Marbury, Hamill, Bachand, Sebree, & Smith, 2003). However, 
the typical AndroGel® application protocol uses 1 gm of a 100 mg/gm product, with 
absorption around 9-10%. Thus, the goal of 14% via intranasal administration is slightly 
higher than the amount delivered transdermally.  
There are no known side effects associated with single dose intranasal testosterone. 
The locally compounded spray poses no additional risks or side effects, and should 
minimize the potential for side effects due to being biologically identical to naturally 
occurring testosterone, as opposed to AndroGel’s synthetic testosterone (Wang et al., 
2004). 
Participants 
Twenty-five participants (40% female) responded to flyers and online postings for 
the pharmacokinetics study. Two female participants were excluded prior to enrollment 
due to medical reasons related to either venipuncture procedures or testosterone 
administration. Three additional participants (one female) were excluded from hormonal 
analysis due to inability to successfully obtain blood samples within four minutes of the 
targeted venipuncture time, resulting in 20 participants who completed the study. Male 
participants reported a mean age of 20.92 (SD 3.04) and BMI of 22.90 kg/m2 (SD 3.65). 
Female participants reported a mean age of 21.14 (SD 2.41) and body-mass index (BMI) 
of 23.50 kg/m2 (SD 3.73). See Table 1 for descriptive statistics. 
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Table 1. Descriptive Statistics of Participants from Study 1 by Sex 
 Male  Female 
 (n = 13)  (n = 7) 
 M / % (SD) / (n)  M / % (SD) / (n) 
Demographics      
Age (years) 20.9 (3.0)  21.1 (2.4) 
BMI (kg/m2) 22.9 (3.7)  23.5 (3.7) 
Ethnicity (Hispanic or Latino) 23.0% (3)  14.3% (1) 
Race      
White 30.1% (4)  57.1% (4) 
Black or African American 7.7% (1)  0.0% (0) 
Asian 38.5% (5)  28.6% (2) 
Other 0.0 % (0)  0.0% (0) 
Serum Testosterone Levels      
Free      
   Baseline 1.4 (0.6)  0.4 (0.3) 
   15 mins post administration 3.2 (2.0)  1.9 (1.4) 
   30 mins post administration 4.4 (2.4)  3.4 (2.0) 
   60 mins post administration 3.7 (2.1)  2.7 (1.8) 
Total      
   Baseline 500.6 (169.7)  50.3 (23.9) 
   15 mins post administration 1255.6 (762.1)  748.9 (617.4) 
   30 mins post administration 1712.1 (912.3)  1386.2 (744.1) 
   60 mins post administration 1334.6 (548.8)  1152.7 (603.8) 
Note. M = mean, SD = standard deviation. Where appropriate, percentage (%) and 
number of participants (n) are provided instead of mean (M) and standard 
deviation (SD). All testosterone levels are represented as ng/dL. 
 
Procedures 
Study participation was completed in a single laboratory visit. Upon arrival to the 
laboratory, experimenters obtained informed consent after detailing study procedures, risks 
associated with testosterone administration and venipuncture, and exclusionary criteria. 
Participants were informed that they could withdraw from the study at any time without 
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penalty. Female participants conducted a mandatory urinary pregnancy test in order to 
ensure safety associated with drug administration due to testosterone’s potential adverse 
effects on the fetus. Negative pregnancy status was verified prior to proceeding with drug 
administration. A staff medical doctor then conducted the first of four 2.5 ml blood draws 
using standard venipuncture protocol. All blood samples were centrifuged prior to blood 
serum isolation and stored at -60 to -80 °C until hormone analysis. 
After providing a baseline blood sample, participants self-administered 14 mg of 
testosterone via intranasal spray (Figure 1). Three further blood draws were taken at 15, 
30, and 60 minutes after spray administration, using independent venipuncture sites for 
each draw. Participants were then debriefed about the purpose of the pharmacokinetic 
study, and compensated $25 USD for study participation. All procedures involving human 
participants were approved and in accordance with the ethical standards of The University 
of Texas at Austin Institutional Review Board (IRB# 2014-12-0029). 
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Figure 1. Testosterone nasal spray 
 
Note. A sterile applicator is applied to individual spray containers immediately prior to use 
for each participant.  
Hormone Analysis 
All serum samples were assayed in-house using commercially available Enzyme-
Linked Immunosorbent Assay (ELISA) kits from DRG International (Springfield, NJ). All 
samples were thawed prior to centrifuge at 3,000 rpm for 15 minutes. Serum sample 
reagents were brought to room temperature (22 °C to 28 °C) prior to beginning analyses. 
Consistent with prior research (Feldman et al., 2002; Vermeulen, Verdonck, & Kaufman, 
1999), intra-assay coefficients of variation (CV) and inter-assays CVs for total and free 
testosterone were each below 8%, values which fit within the acceptable range. 
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Statistical Analysis 
Descriptive statistics, independent samples t-tests comparing total and free 
testosterone mean concentrations between males and females, and paired samples t-tests 
comparing post-administration time points (i.e., 15, 30, and 60) to baseline, were conducted 
using SPSS version 21.0 (Armonk, NY).  
In addition, area under the curve with respect to increase (AUCI) and area under the 
curve with respect to ground (AUCG) were separately calculated for males and females to 
determine total and free testosterone increase, and total and free testosterone output, 
respectively (Pruessner, Kirschbaum, Meinlschmid, & Hellhammer, 2003). AUC values 
were then compared between males and females using independent samples t-tests. 
RESULTS 
Overall, total and free testosterone increased in a linear fashion at 15- and 30-
minutes post testosterone administration, peaking at 30 minutes, and declining 60 minutes 
following administration (see Figures 11 and 12 in the Appendix for individual participant 
plots).  
As expected, male and female participants differed significantly in baseline total 
(t(18) = -6.898, p < .000) and free (t(18) = -4.013, p = .001) testosterone levels. Mean total 
and free concentrations did not differ significantly between male and female participants 
for other time points (all p’s > .05). 
Further, male and female participants did not differ significantly from each other in 
terms of increase (AUCI) in total or free testosterone from baseline, nor total or free 
testosterone output (AUCG) (all p’s > .05). 
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Males 
Male participants’ total testosterone concentrations increased from baseline values 
of 500.57 ng/dL (SD 169.67) to 1255.57 ng/dL (SD 762.09) 15 minutes post-
administration, peaking at 1712.10 ng/dL (SD 912.32) 30 minutes post-administration, and 
declining to 1334.62 ng/dL (SD 548.80) 60 minutes post-administration. This 
corresponded to increases in total testosterone concentrations by 150.8% (t(12) = -3.948, p 
= .002, d = 1.368), 242.0% (t(11) = -5.014, p < .001, d = 1.846), and 166.6% (t(10) = -
5.989, p < .001, d = 2.053) over baseline levels at the 15, 30, and 60 minute time points, 
respectively (see Figure 2 for a plot of this data).  
Figure 2. Total serum testosterone concentrations by sex 
 
Note. Error bars indicate individual standard error for each time point separately for males 
and females. 
Male participants’ free testosterone concentrations increased from baseline values 
of 1.39 ng/dL (SD 0.62) to 3.24 ng/dL (SD 1.98) 15 minutes post-administration, peaking 



























2.15) 60 minutes post-administration. This corresponded to increases in total testosterone 
concentrations by 133.1% (t(12) = -4.324, p = .001, d = 1.261), 218.7% (t(11) = -4.873, p 
< .001, d = 1.728), and 166.2% (t(10) = -3.982, p = .003, d = 1.460) over baseline levels at 
the 15, 30, and 60 minute time points, respectively (see Figure 3 for a plot of this data). 
Figure 3. Free serum testosterone concentrations by sex 
 
Note. Error bars indicate individual standard error for each time point separately for males 
and females. 
Females 
Female participants’ total testosterone concentrations increased from baseline 
values of 50.34 ng/dL (SD 23.88) to 748.93 ng/dL (SD 617.40) 15 minutes post-
administration, peaking at 1386.25 ng/dL (SD 744.11) 30 minutes post-administration, and 
declining to 1152.72 ng/dL (SD 603.76) 60 minutes post-administration. This 
corresponded to increases in total testosterone concentrations by 1387.7% (t(5) = -2.692, p 





























4.397, p = .007, d = 2.580) over baseline levels at the 15, 30, and 60 minute time points, 
respectively (see Figure 2 for a plot of this data). 
Female participants’ free testosterone concentrations increased from baseline 
values of 0.36 ng/dL (SD 0.34) to 1.89 ng/dL (SD 1.44) 15 minutes post-administration, 
peaking at 3.35 ng/dL (SD 2.01) 30 minutes post-administration, and declining to 2.69 
ng/dL (SD 1.77) 60 minutes post-administration. This corresponded to increases in free 
testosterone concentrations by 425.0% (t(6) = -2.797, p = .031, d = 1.462), 830.6% (t(6) = 
-3794, p = .009, d = 2.074), and 647.2% (t(6) = -3.644, p = .011, d = 1.828) over baseline 
levels at the 15, 30, and 60 minute time points, respectively (see Figure 3 for a plot of this 
data). 
DISCUSSION 
The present study established the pharmacokinetic profile of a novel intranasal 
testosterone delivery system in both healthy men and women. In contrast to existing 
testosterone pharmacokinetic studies sampling mostly hypogonadal men, the present study 
fills a critical gap in the literature by employing a healthy, eugonadal sample of both men 
and premenopausal women.  
Due to paucity of exogenous testosterone pharmacokinetic data from eugonadal 
men, direct comparisons of time to peak concentrations and percent increase from baseline 
are limited. In the present study, 13 eugonadal men reached mean peak total serum 
concentrations (1712.10 ng/dL) 0.5 hours following administration of 14 mg testosterone 
via intranasal spray, resulting in 242.0% increase from baseline (500.57 ng/dL). In 
comparison, five eugonadal men reached mean peak total serum concentrations (1956 
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ng/dL) 0.5 hours following administration of 10 mg testosterone via transbuccal tablet, 
resulting in 531.0% increase from baseline (approximately 310 ng/dL) (Kim, Snipes, 
Hodgen, & Anderson, 1995). It is worth noting that baseline total serum concentrations 
were significantly lower in the transbuccal study (approximately 310 ng/dL, Kim et al., 
1995), than in the present study (500.57 ng/dL), which may have resulted in ceiling effects 
in the present study. 
Although a direct comparison to the present study is not appropriate due to 
differences in gonadal status, in a sample of eight hypogonadal men, participants reached 
mean peak total serum concentrations 1.4 hours following 15.2 mg intranasal gel 
administration, resulting in approximately 514.6% increase from baseline (Mattern et al., 
2008). In another study with 29 hypogonadal men, participants reached mean peak total 
serum concentrations 18 hours following 50 mg transdermal gel administration, resulting 
in approximately 140.0% increase from baseline (Marbury et al., 2003).  
Few exogenous testosterone pharmacokinetic studies are available in healthy, 
premenopausal women. In the present study, 6 eugonadal, premenopausal women reached 
mean peak total serum concentrations (1386.25 ng/dL) 0.5 hours following administration 
of 14 mg testosterone via intranasal spray, resulting in 2653.6% increase from baseline 
(50.34 ng/dL). In comparison, 16 eugonadal, premenopausal women reached mean peak 
total serum concentrations (673 ng/dL) 0.23 hours following administration of 0.75 mg 
testosterone via sublingual solution, resulting in 3265% increase from baseline (20 ng/dL) 
(van Rooij et al., 2012).  
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One other comparison comes from an unpublished report in which 0.5 mg of 
sublingual testosterone administration in healthy premenopausal women resulted in “a 
tenfold increase in total testosterone” 15 minutes after intake, or approximately a 1000% 
increase from baseline (Tuiten & van Honk, unpublished data; Tuiten et al., 2000). Time 
to peak concentration, and peak percent increase from baseline were not reported. 
Overall, time to peak concentrations and percent testosterone increase from 
baseline to peak concentrations obtained from the present study were comparable to 
transbuccal and sublingual administration studies with eugonadal men and women. 
However, unlike the direct-to-central-nervous-system delivery associated with intranasal 
testosterone (via direct transmission through trigeminal and olfactory nerve pathways), oral 
administration of testosterone (e.g., transbuccal and sublingual) is subject to metabolic 
degradation, and associated with increased risk of liver damage (Gluud et al., 1983; 
Werner, Hanger, & Kritzler, 1950). Compared to studies using similar administrative route 
(i.e., intranasal), the testosterone spray used in the present study resulted in shorter time to 
peak concentration, likely due to the usage of a more readily absorbed aqueous form of 
testosterone, compared to a viscous intranasal gel. Moreover, unlike studies using 
transdermal administration, the testosterone spray in the present study resulted in larger 
testosterone percent increase from baseline and few, if any, risks associated with 
unintended, secondary contamination. 
As with any study, the present findings must be interpreted in light of limitations. 
First, the study was conducted utilizing a convenience sample consisting of participants 
relatively similar in terms of age, body mass, and gonadal status. Replication of findings 
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using heterogeneous samples is needed. Second, since pharmacokinetic analysis was the 
primary outcome of interest, the present study was not blinded and did not include an active 
comparator or a placebo control. Third, the pharmacokinetic data does not extend beyond 
60 minutes following the baseline sample. Relative to the 30-minute time point, both free 
and total testosterone levels for men and women are lower, suggesting the beginning of the 
descending limb. Nonetheless, an extension of the present study with serum samples 
throughout a 24-hour observational period is needed. Fourth, the present study had a 
relatively small sample of 20 participants; and individual pharmacokinetic profiles indicate 
heterogeneity among participants’ responses (Figures 11 and 12). Replication with a larger 
sample would be helpful in bolstering the present findings, particularly with regard to 
timing of peak testosterone concentrations. Fifth, testosterone administration may have 
impacted endogenous testosterone production. Levels of gonadal hormones in the brain are 
typically modulated via a negative feedback loop. In a healthy brain, gonadotropin-
releasing hormone (GnRH) from the hypothalamus signals the production and secretion of 
the gonadotropins, including luteinizing hormone (LH) and follicle-stimulating hormone 
(FSH). Once the gonadotropins are secreted into the blood stream, LH acts on its receptor 
in the gonads, which in turn stimulates the release of the sex steroids, such as testosterone. 
Testosterone then complete the negative feedback loop by inhibiting the release of GnRH 
(Blair, McGee, Bhatta, Palm, & Casadesus, 2015). It is possible that exogenous 
testosterone may have inhibited the production of endogenous testosterone through the 
negative feedback loop. Sixth, the time of day for testosterone administration was not 
controlled. Levels of testosterone follow a diurnal pattern, with levels peaking between 
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0530 and 0800 h, and trough levels occurring approximately 12 hours later (Brambilla, 
Matsumoto, Araujo, & McKinlay, 2009; Bremner, Vitiello, & Prinz, 1983; Cooke, 
McIntosh, & McIntosh, 1993; de la Torre, Sjöberg, Hedman, Bártfai, & Diczfalusy, 1981; 
Diver, Imtiaz, Ahmad, Vora, & Fraser, 2003). It would be important to account for 
differences in endogenous testosterone levels based on time of day in future studies. Lastly, 
the intranasal administration of testosterone resulted in post-nasal drip, which prohibited 
salivary testosterone samples from being effectively assayed due to contamination, and 
therefore no salivary data is available.  
Despite these limitations, this study provides essential evidence for the 
effectiveness and utility of intranasally-delivered testosterone in both healthy men and 
women, and demonstrates a novel mode of exogenous testosterone administration for 
psychological research purposes.
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Chapter 3: Effects of Exogenous Testosterone on Subjective Anxiety 
ABSTRACT 
Can a single-dose of a testosterone-containing nasal spray reduce anxiety? 
Although both exogenous and endogenous testosterone have been associated with 
reductions in implicitly measured fear responses, it remains unknown whether exogenous 
testosterone can reduce the explicit, subjective experience of anxiety in humans. In the 
present study, participants (N = 104, 48.1% female) were randomly assigned to receive 
either testosterone or placebo via intranasal spray before taking part in an acute 
psychosocial stressor. Participants used visual analogue scales to rate their subjective 
anxiety before, during, and after the stressor. Results revealed a statistically significant 
drug by sex interaction, in which women—as expected—experienced significantly higher 
levels of subjective anxiety in the placebo condition compared to men; a sex difference that 
was eliminated in the drug condition. Further, women randomized to the testosterone 
condition experienced significantly lower levels of anxiety during recovery from the acute 
stressor relatively to women in the placebo condition. Taken together, these results have 
important implications for the etiology of anxiety and treatment. 
BACKGROUND 
Due to the vital role that fear plays in the survival of the organism, the distinction 
between normal and pathological anxiety is one of degree rather than kind (Beck & Clark, 
1997). Anxiety disorders are characterized by excessive fear and behavioral avoidance in 
response innocuous stimuli (American Psychiatric Association, 2013), and has the highest 
prevalence of all psychiatric diagnoses (Kessler, Berglund, et al., 2005; Kessler, Chiu, et 
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al., 2005). Globally, 1 in every 3 people will be diagnosed with an anxiety disorder in their 
lifetime (Baxter, Scott, Vos, & Whiteford, 2013), with prevalence and severity twice as 
high in women than men (Baxter et al., 2013; Gater et al., 1998; McLean et al., 2011). 
Testosterone has been linked to fear reduction and reductions in anxiety-related behaviors 
(Enter, Spinhoven, et al., 2016; Enter, Terburg, et al., 2016; Giltay et al., 2012), prompting 
researchers to point to sex differences in testosterone concentrations as a plausible 
explanation for the greater prevalence of anxiety disorders in women (Giltay et al., 2012; 
McHenry et al., 2014; Toufexis, Myers, & Davis, 2006). 
Anxiolytic effects of testosterone have been observed in measures of anxiety-like 
behavior in rodents. Gonadectomy in adult male rodents results in increased anxiety-like 
behaviors in a battery of behavioral tests, including the elevated plus maze, open field test, 
and defensive probe-burying, compared to sham-operated controls (Adler et al., 1999; 
Fernández-Guasti & Martínez-Mota, 2003; Frye & Seliga, 2001; Morsink et al., 2007; Slob 
et al., 1981), effects that were reversed by testosterone replacement (Adler et al., 1999; 
Fernández-Guasti & Martínez-Mota, 2005; Frye & Seliga, 2001; Slob et al., 1981). 
Moreover, testosterone replacements were equally as effective as the administration of the 
typical tricyclic antidepressant imipramine in alleviating anxiety-like behaviors induced by 
two-weeks of chronic social isolation (Carrier & Kabbaj, 2012). In intact adult female 
rodents, injections of testosterone or its metabolites reduced anxiety-like behaviors in the 
open field test, elevated plus maze (Frye & Lacey, 2001), and defensive burying 
(Gutiérrez-García et al., 2009), compared to vehicle-treated controls.  
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To date, only a handful of experimental studies have directly tested the anxiolytic 
effect of testosterone in humans. Consistent with animal research, compared to placebo-
treated controls, administration of testosterone resulted in diminished preconscious 
selective attention to threatening stimuli (van Honk et al., 2005), reduced gaze avoidance 
in individuals with social anxiety disorder (Enter, Terburg, et al., 2016), reduced fear-
potentiated startle response (Hermans et al., 2006), and increased behavioral approach 
(Enter et al., 2014; Enter, Spinhoven, et al., 2016). 
Although quite promising, there are several limitations associated with existing 
testosterone administration studies in humans. First, no male subjects were tested in 
conjunction with females, raising several important questions. Second, despite the fact that 
the majority of clinical assessments of anxiety require patients to report on their subjective 
experiences of anxiety, limited research has examined the effect of exogenous testosterone 
on self-reported anxiety. Of the few existing studies, all have reported null effect of drug 
administration (e.g., Hermans et al., 2007; van Honk et al., 2005). In addition to the 
possibility that testosterone has no effect on subjective anxiety, it is plausible that these 
null effects were the result of an insufficiently emotionally provocative task. Specifically, 
van Honk et al. (2005) used an emotional Stroop task, which has not been consistently 
associated with self-reported measures of anxiety (e.g., Amir et al., 1996; Becker, Rinck, 
Margraf, & Roth, 2001; de Ruiter & Brosschot, 1994; Egloff & Hock, 2001; Richards, 
French, Johnson, Naparstek, & Williams, 1992). Third, considering that clinical 
assessment and diagnosis of anxiety via emotional Stroop or startle response in clinical 
settings is not feasible nor appropriate, but is rather accomplished via a patient’s subjective 
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assessment of his or her anxiety, a more clinically valid test of the putative anxiolytic 
effects of exogenous testosterone in response to ecologically valid stimuli is warranted. 
The Trier Social Stress Test (TSST), originally developed as a tool to elicit 
psychosocial stress in the laboratory, incorporates public speaking as a part of its protocol 
(Kirschbaum, Pirke, & Hellhammer, 1993). Considering that public speaking is one of the 
most common fears in the general population (Stein, Torgrud, & Walker, 2000; Stein, 
Walker, & Forde, 1994, 1996), it is not surprising that the induction of the TSST is 
consistently associated with significant increases in self-reported stress and anxiety (Allen, 
Kennedy, Cryan, Dinan, & Clarke, 2014), making it a robust, anxiety-eliciting task for 
laboratory research. 
Moreover, unlike observations of behavioral outcomes (e.g., magnitude of startle 
response), which do not reliably distinguish between different emotional states (e.g., 
Cornwell, Johnson, Berardi, & Grillon, 2006; Elsesser, Sartory, & Tackenberg, 2004; 
Kaviani et al., 2004; Vrana, Spence, & Lang, 1988), self-report scales are easy to 
administer and provide a better assessment of subjective experiences (Flynn, van Schaik, 
& van Wersch, 2004; Hasson & Arnetz, 2005). Of various self-report measures, visual 
analogue scales offer superior measurement characteristics by allowing for greater 
variances in scores compared to traditional Likert scales (Flynn et al., 2004; Hasson & 
Arnetz, 2005). In particular, visual analogues are less susceptible to memory effects 
(Hasson & Arnetz, 2005), and thus can be effectively administered repeatedly throughout 
a study (e.g., Ali, Nitschke, Cooperman, & Pruessner, 2017). As a result, rather than using 
a single measure to capture the subjective experience of anxiety in response to a stimulus, 
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repeated measures allows for more nuanced assessment of changes over time, and also the 
computation of metrics such as stress-evoked subjective anxiety (AUCI) (Ali et al., 2017; 
Pruessner et al., 2003). 
Further, repeated measures of subjective anxiety over time allows for the 
comparison of intervals of interest across the course of reactivity. One period of interest is 
recovery following exposure to the TSST. Slower and poorer recovery following acute 
stress has been associated with greater anxiety symptoms (reviewed in Chida & Hamer, 
2008). Presently, it is not clear whether exogenous testosterone has any effect on 
psychological recovery following acute stress. 
Taken together, existing research point to several gaps in the current literature. The 
present study aims to fill these gaps by investigating possible effects of testosterone 




A mixed-sex, repeated measures research design was used to examine the effects 
of single-dose, intranasal testosterone administration in response to the TSST. Participants 
were randomized to receive placebo or testosterone administration via intranasal spray (see 
Study 1). In addition to baseline trait measures, acute self-reported anxiety was assessed 
across multiple time points corresponding to pre-, during-, and post-stressor using visual 
analogue scales. All procedures involving human participants were approved and in 
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accordance with the ethical standards of The University of Texas at Austin Institutional 
Review Board (IRB# 2015-07-0024). 
Participants 
Power Analysis 
Based on medium to large effect sizes seen in previous testosterone administration 
studies in humans (e.g., Bos, van Honk, Ramsey, Stein, & Hermans, 2013; Hermans, 
Putman, Baas, et al., 2006; Hermans, Ramsey, & van Honk, 2008; van Honk et al., 2004), 
the present study was powered to identify a medium effect size. Power analyses using 
G*Power 3 (Faul, Erdfelder, Lang, & Buchner, 2007), with alpha set to .05, indicated that 
a sample size of 110 participants would have greater than .80 power to detect a medium 
effect (f = .3) between conditions. 
Descriptive Statistics 
One hundred and ten participants registered in an introductory psychology class 
from The University of Texas at Austin enrolled in the study for course credit. Eligible 
participants were English-speaking adults between ages 18-30 with body mass index (BMI) 
between 17 kg/m2 and 35 kg/m2. Participants were excluded if they had history of any 
psychological or physical illness, or medication use that would impact endocrine 
functioning or preclude testosterone administration. In addition, participants with daily 
recreational drug use (including, but not limited to, nicotine and alcohol), were excluded 
from participation. Female participants currently using hormonal birth control, or 
experiencing irregular periods were also excluded from participation.  
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Of the 110 participants enrolled in the study, two participants did not complete the 
study due to adverse effects associated with the TSST. Three participants were not able to 
complete the study due to discomfort or difficulties associated with nasal spray 
administration. And one participant was excluded from data analyses due to incomplete 
data. 
The final sample of 104 participants (48.1% female) was approximately one-third 
Hispanic or Latino (28.8%), one-third Asian (31.7%), and one-third White (29.8%), with 
mean age of 19.05 ± 1.05 years and BMI of 23.06 ± 3.18 kg/m2. Most participants were 
born in the United States (78.8%), and nearly half (56.7%) spoke language(s) other than 
English (see Table 2 for demographic characteristics by sex).
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Table 2. Descriptive Statistics of Participants from Study 2 by Group and Sex 
  Placebo (n = 52)  Testosterone (n = 52) 
 Male (n = 27) Female (n = 25)  Male (n = 27) Female (n = 25) 
  M / % (SD) / (n) M / % (SD) / (n)  M / % (SD) / (n) M / % (SD) / (n) 
Demographics          
Age (years) 19.2 (1.3) 19.1 (0.9)  19.0 (0.9) 18.8 (1.0) 
BMI (kg/m2) 22.6 (2.5) 23.4 (3.9)  23.3 (2.6) 23.0 (3.7) 
Ethnicity (Hispanic or Latino) 29.6% (8) 32.0% (8)  25.9% (7)  (6) 
Race          
White 33.3% (9) 40.0% (10)  33.3% (9) 16.0% (4) 
Black or African American 3.7% (1) 12.0% (3)  3.7% (1) 20.0% (5) 
Asian 33.3% (9) 16.0% (4)  37.0% (10) 36.0% (9) 
Other 0.0% (0) 0.0% (0)  0.0% (0) 4.0% (1) 
Born in the US (Yes) 70.3% (19) 92.0% (23)  85.2% (23) 68.0% (17) 
Speak language(s) other than 
English (Yes) 70.0% (19) 48.0% (12)  51.9% (14) 56.0% (14) 
Baseline Measures          
Depression (CESD) 11.6 (6.6) 13.1 (7.6)  11.9 (7.0) 11.7 (7.3) 
Anxiety (BAI) 7.6 (5.9) 10.1 (7.3)  6.3 (5.7) 7.2 (7.4) 
Anxiety Sensitivity (ASI-3) 14.9 (9.9) 16.6 (9.8)  13.7 (8.2) 12.4 (11.8) 
Social Anxiety (FNES) 13.6 (7.7) 16.6 (6.5)  13.7 (8.2) 13.5 (7.7) 
Baseline Subjective Anxiety 
(VAS) 1.7 (1.8) 1.9 (1.8)  1.8 (1.6) 1.7 (1.7) 
Note. M = mean, SD = standard deviation. Where appropriate, percentage (%) and number of participants (n) are 




All female participants were scheduled during the estimated mid-luteal phase of 
their menstrual cycles (between 17th and 24th day following the most recent onset of 
menstruation) in order to minimize the possible effects of cycling gonadal hormones on 
endocrine response (Kirschbaum et al., 1993; Viau, 2002). To assess cycle phase, female 
participants were asked to recall the first day of their most recent menstruation during a 
telephone screening. Male participants were scheduled according to the availability of 
laboratory facilities and the experimenter. 
Pregnancy Test 
Following informed consent, all female participants conducted a mandatory urinary 
pregnancy test (Wondfo Pregnancy Strips, Willowbrook, IL) due to testosterone’s potential 
adverse effects on the fetus. Negative pregnancy status was verified prior to proceeding 
with drug administration. 
Baseline Questionnaires 
All participants completed baseline measures of depression, anxiety, anxiety 
sensitivity, and fear of negative evaluation (social anxiety) prior to testosterone 
administration. 
Testosterone Administration 
Participants were randomized to either placebo or testosterone (stratified by sex) 
using a random sequence generated at randomizer.org. Experimenters and participants 
were blind to the drug condition. All participants self-administered an aqueous solution 
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containing either 14 mg testosterone propionate or placebo, via intranasal spray (Figure 1). 
Participants were instructed to insert a sterile applicator into one nostril and to pump until 
they felt a full strong spray. Once they felt a full spray, participants were instructed to 
inhale and alternate between their nostrils until the container is empty. After the self-
administration of the nasal spray, participants were asked to relax for 30-minutes to allow 
for absorption of the hormone. The protocol for intranasal testosterone administration is 
based on the pharmacokinetic data from Study 1. In Study 1, using the same protocol, 
dosage, and formulation as used here in Study 2, blood samples obtained via venipuncture 
showed peak levels for both free (bioavailable) and sex hormone-binding globulin 
(SHBG)-bound testosterone 30 minutes post-administration in both men and women, 
which coincide with the start time of the public speaking challenge in the present study 
(see below). 
Public Speaking Challenge 
Thirty minutes following testosterone administration, all participants began the 
Trier Social Stress Test (Birkett, 2011; Kirschbaum et al., 1993). Participants first provided 
a baseline assessment of subjective anxiety using a visual analogue scale. Immediately 
after, participants were brought in front of one male and one female confederate and told 
via a pre-recorded message that they will give a speech of their qualifications for their ideal 
job to the panel of behavioral experts in front of them. Participants were informed that the 
behavioral experts will assess their verbal and non-verbal skills, and that their performance 
will be video recorded for subsequent analyses. Participants were then escorted to a quiet 
preparatory room, where they were told they had ten minutes to prepare their oral 
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presentations. In reality, each participant was timed for eight minutes before they were 
interrupted.  
Immediately prior to their speeches, participants were asked to complete a second 
visual analogue scale corresponding to anticipatory anxiety. When the five minutes allotted 
for their speeches elapsed, participants were asked to count down from 1,022 in decrements 
of 13. If an incorrect response was given at any point in the countdown sequence, 
participants were interrupted and instructed to begin again at 1,022. Participants were given 
five minutes to complete the countdown and asked to “please continue” if they did not 
produce an answer after 10 seconds. The confederates on the panel were trained not to 
provide any verbal or behavioral reinforcement, and were instructed to remain impassive 
throughout the course of the study. 
Following their speeches and mental arithmetic, participants were escorted back to 
the preparatory room to complete a third visual analogue scale assessing subjective anxiety. 
Once 10 minutes elapsed, a fourth visual analogue scale was collected. After the collection 
of the last visual analogue scale, participants were debriefed, awarded five credits for study 
participation, and dismissed. See Figure 4 for study timeline. 
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Figure 4. Trier Social Stress Test data collection timeline 
 
Note. Visual analogue scales are collected every 10 minutes throughout the study. 
Measures 
Baseline Clinical Measures 
The Center for Epidemiologic Studies Depression Scale (CESD; Radloff, 1977) is 
a 20-item, multiple choice (ranging from “rarely or none of the time” to “most or all of the 
time”) self-report questionnaire designed to measure levels of depressive symptomatology 
in the past week. The CESD assesses symptoms such as inattentiveness and irritability; 
cognitions such as hopelessness; and physical symptoms such as a lack of appetite and 
restless sleep. 
The Beck Anxiety Inventory (BAI; Beck, Epstein, Brown, & Steer, 1988) is a 21-
item multiple choice (ranging from 0 to 3) self-report questionnaire designed to measure 
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levels of anxious symptomatology. The BAI assesses symptoms such as numbness and 
tingling, fear of losing control, and catastrophizing. 
The Anxiety Sensitivity Index-3 (ASI-3; Taylor et al., 2007) is an 18-item self-
report questionnaire designed to assesses physical, cognitive, and social concerns 
associated with the fear of arousal-related sensations. Respondents are asked to rate the 
extent to which the 18 items describe themselves using five-point Likert scales (ranging 
from 0 or “very little” to 4 or “very much”). 
The Fear of Negative Evaluation Scale (FNES; D. Watson & Friend, 1969) is a 30-
item, self-report questionnaire designed to measure social anxiety. Respondents are asked 
to indicate whether each statement is true or false of their personality (e.g., “I rarely worry 
about seeming foolish to others.”). If the choice is difficult, respondents are asked to select 
the response that is most applicable at the moment. 
Acute Subjective Anxiety 
A visual analogue scale assessing acute state anxiety was developed for the purpose 
of this study. Participants were asked to self-report their anxiousness by indicating a 
position along a continuous line between two end-points: 0 for “not at all anxious” and 10 
for “extremely anxious” in response to the prompt “please indicate how anxious you are 
right now.” An example of the visual analogue scale is included as Figure 5. 
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Figure 5. Visual analogue scale for subjective anxiety 
 
Note. Responses for each time point were measured using a ruler and recorded to the 10th 
decimal place. 
Data Analytic Plan 
Pre-Drug Administration Group Comparisons 
Multiple one-way between-subjects analysis of variance (ANOVA) were 
conducted to test whether there were mean group differences in age, BMI, baseline 
subjective anxiety, depression, anxiety, anxiety sensitivity, and fear of negative evaluation 
across the four groups (male placebo, female placebo, male testosterone, female 
testosterone). 
Group Differences in Subjective Anxiety Across Sexes and Drug Conditions 
A two-way univariate ANOVA was conducted to test group differences in 
subjective anxiety across sexes and drug conditions. A single value of area under the curve 
with respect to increase (AUCI) was calculated for each participant to represent stress-
evoked subjective anxiety (Ali et al., 2017; Pruessner et al., 2003). Simple main effects 
were analyzed following significant interaction between sex and drug condition. 
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Recovery Comparisons 
Independent samples t-tests were conducted to test within-sex differences in 
psychological recovery following the TSST between placebo and the drug condition. A 
single delta value between time point 2 (peak, anticipatory anxiety) and time point 3 (first 
recovery time point following the stressor) was calculated for each participant to represent 
psychological recovery. 
Moderation Analyses 
Multiple linear regressions were conducted to test moderating effects of trait 
measures for depression (CESD; Radloff, 1977), anxiety (BAI; Beck, Epstein, Brown, & 
Steer, 1988), anxiety sensitivity (ASI-3; Taylor et al., 2007), and fear of negative 
evaluation (FNES; D. Watson & Friend, 1969) on drug condition in predicting subjective 
anxiety. Analyses were conducted separately for males and females for ease of 
interpretation (i.e., two-way versus three-way interactions). 
RESULTS 
Pre-Drug Administration Group Comparisons 
Across four groups (male placebo, female placebo, male testosterone, female 
testosterone), participants did not differ significantly in age (F(3,100) = .753, p = .523), 
BMI (F(3,100) = .338, p = .798), baseline subjective anxiety (F(3,100) = .073, p = .974), 
depression symptomatology (F(3,100) = .238, p = .869), anxiety symptomatology 
(F(3,100) = 1.555, p = .205), anxiety sensitivity (F(3,100) = .806, p = .493), or fear of 
negative evaluation (F(3,100) = 1.01, p = .392). See Table 2 for baseline descriptive 
statistics. 
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Group Differences in Subjective Anxiety Across Sexes and Drug Conditions 
There was a significant two-way interaction between sex and drug condition for 
stress-evoked subjective anxiety (AUCI: F(1,100) = 4.309, p = .04). Additional simple 
main effects are reported below. See Figure 6 for changes in subjective anxiety across time, 
Figure 7 for a plot of the AUCI interaction, and Figure 13 in the Appendix for individual 
participant plots of changes in subjective anxiety across time. 
Figure 6. Subjective anxiety by sex, drug condition, and time 
 
Note. Error bars indicate individual standard error for each time point separately for males 







































Figure 7. Sex by drug condition interaction in subjective anxiety 
 
Note. Error bars indicate standard error.  
Across Drug Conditions 
A statistically significant difference in subjective anxiety was observed between 
men and women in the placebo condition (t(50) = 2.856, p = .006, d = .788), such that 
women reported significantly higher levels of subjective anxiety than men. No difference 
in subjective anxiety was observed between men and women in the drug condition (t(50) 
= .108, p = .915, d = 0.030); in other words, testosterone administration reduced the sex 
difference observed in the placebo condition to non-significance. 
Across Sexes 
No difference in subjective anxiety was observed between women randomized to 
the placebo condition versus the drug condition (t(48) = 1.213, p = .231, d = 0.343), nor 
between men randomized to the placebo condition versus the drug condition (t(52) = -




























There was a significant difference in post-stressor recovery between the placebo 
and drug condition in women (t(48) = 2.154, p = .036, d = 0.609), such that there was an 
increase in subjective anxiety in the placebo condition, but a decrease in anxiety in the 
testosterone condition from peak to recovery. No difference in post-stressor recovery was 
observed between men randomized to the placebo condition versus the drug condition 
(t(52) = .417, p = .678, d = 0.113). 
Moderation Analyses 
Males 
Changes in subjective anxiety across drug conditions was not moderated by 
measures of depression (β = 0.179, p = 0.576), anxiety (β = 0.366, p = 0.128), anxiety 
sensitivity (β = 0.404, p = 0.146), or fear of negative evaluation (β = 0.224, p = 0.480). 
Females 
Changes in subjective anxiety across drug conditions was not moderated by 
measures of depression (β = 0.470, p = 0.121), anxiety (β = 0.113, p = 0.653), anxiety 
sensitivity (β = -0.233, p = 0.378), or fear of negative evaluation (β = -0.070, p = 0.845). 
DISCUSSION 
The present study examined the joint influence of sex and 14 mg testosterone 
administration on self-reported anxiety, in response to a psychosocial challenge. To date, 
this is the first study to test healthy male and female subjects in parallel using the same 
exogenous testosterone administration protocol. Results revealed a statistically significant 
sex by drug interaction, in which women experienced significantly higher levels of stress-
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evoked subjective anxiety in the placebo condition compared to men, a sex difference that 
was eliminated in the drug condition. These differences were not moderated by individual 
differences in depression, anxiety, anxiety sensitivity, or fear of negative evaluation. 
Considering the substantial, pervasive sex differences in the prevalence of anxiety 
disorders worldwide (Gater et al., 1998; McLean et al., 2011), this finding is particularly 
noteworthy, and suggests that sex differences in health disparity may be mediated by 
differences in levels of testosterone. Further, results demonstrate that women reported 
significantly less subjective anxiety during recovery to acute stress following testosterone 
administration versus placebo administration. A significant body of research suggest that 
slower recovery from acute stressors is a significant risk factor for the development and 
maintenance of both psychological and physical illnesses (reviewed in Brosschot, Pieper, 
& Thayer, 2005; Burke, Davis, Otte, & Mohr, 2005; Chida & Hamer, 2008). Specifically, 
the failure to shut down the stress response results in greater exposure to hormones such as 
cortisol, which has significant deleterious effects on health following prolonged exposure 
(McEwen, 1998; McEwen & Stellar, 1993; Sapolsky, Romero, & Munck, 2000). This 
finding suggests that the anxiolytic effects of testosterone may be exerted through its 
protective effects during acute stress recovery. 
Anxiety disorders are associated with both structural and functional abnormalities 
within the amygdala and hippocampus (Shin & Liberzon, 2010), two brain regions that 
appear to be strongly influenced by testosterone (McHenry et al., 2014). In both humans 
and rodents, the amygdala plays a major role in modulating anxiety and fear responses 
(reviewed in Rauch, Shin, & Wright, 2003; Ressler, 2010; Rodrigues, LeDoux, & 
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Sapolsky, 2009). Hyperactivity of the amygdala has been associated with increased anxiety 
symptoms in humans (Shin & Liberzon, 2010), and in rodents models (Singewald, 2007). 
Consistent with findings of the present study, neuroimaging studies examining the 
anxiolytic effects of testosterone found sexually divergent associations between 
testosterone and amygdala activation. Specifically, greater levels of testosterone are 
associated with increased amygdala activation in men (Derntl et al., 2009), but not in 
women (Stanton et al., 2009).  
The hippocampus has also been extensively documented as a critical site involved 
in anxiety disorders. Structural abnormalities and reduced activity in the hippocampus are 
observed in individuals with anxiety disorders, compared to healthy controls (Ferrari, 
Busatto, McGuire, & Crippa, 2008). Chronic stress is associated with hippocampi atrophy 
and impaired neurogenesis (McEwen & Magarinos, 2001). These effects can impair 
memory, impact hypothalamic-pituitary-adrenal axis negative feedback, and contribute to 
the development of anxiety symptoms (Revest et al., 2009). With regard to present 
findings, there is evidence suggesting that adult hippocampal neurogenesis is sexually 
dimorphic, with females exhibiting higher cell proliferation than males (Galea & McEwen, 
1999). Preclinical evidence suggests that testosterone exerts anxiolytic and protective 
cellular effects in the hippocampus. Although its underlying mechanisms are not clearly 
understood, some of the protective effects of testosterone in the hippocampus may be due 
to testosterone’s ability to lessen the aversive effects of stress and facilitate molecular 
mechanisms that favor cell proliferation, growth and/or survival (Galea & McEwen, 1999; 
McEwen, 1998; McEwen & Stellar, 1993). 
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In addition to sexual dimorphism in the amygdala and the hippocampus, sex 
differences in subjective anxiety following testosterone administration may also be 
explained in part by sex differences in the salience of instrumentally oriented tasks that 
speak directly to one’s competence, such as public speaking challenges (Stroud, Salovey, 
& Epel, 2002). Instrumental traits (e.g., dominance, competitiveness, and self-confidence) 
tend to be more central to men’s self-construal than to women’s (Cross & Madson, 1997), 
which may lead to greater desire to maintain social status (Josephs, Newman, Brown, & 
Beer, 2003; Josephs, Sellers, Newman, & Mehta, 2006; Lee, Gino, Jin, Rice, & Josephs, 
2015; Mehta & Josephs, 2010; Mehta, Lawless DesJardins, van Vugt, & Josephs, 2017; 
Sherman, Lerner, Josephs, Renshon, & Gross, 2016). Testosterone administration in men 
may further highlight the salience associated with status, and thus increase anxiety due to 
the enhanced sense of failure created by the Trier Social Stress Test, regardless of one’s 
objective performance. Additional research using stressors that more salient to women 
(e.g., a social rejection stressor) with a mix-sex sample is warranted to better understand 
the underlying mechanism associated with sex differences in the present study. 
Differences in subjective anxiety during recovery between women randomized to 
placebo versus testosterone may be explained in part by differences in rumination due to 
perceived failure. In particular, administration studies in healthy females show that 
exogenous testosterone rapidly reduces functional coupling of the amygdala with the 
orbitofrontal cortex, and enhanced amygdala coupling with the thalamus (van Wingen et 
al., 2010). Specifically, this decoupling decreases emotional rumination by either inhibiting 
signals from the amygdala to the orbitofrontal cortex, or redirecting those signals away 
 60 
from the orbitofrontal cortex (van Wingen, Ossewaarde, Bäckström, Hermans, & 
Fernández, 2011). It is possible that one of the mechanisms for reduced subjective anxiety 
is reductions in rumination following perceived failure. 
 The finding that exogenous testosterone is associated with lower subjective anxiety 
and faster recovery in response to stress has significant clinical implications. Extensive 
research suggests that slower psychological recovery following acute stress (i.e., 
rumination), is associated with greater anxiety symptoms (McLaughlin & Nolen-
Hoeksema, 2011; Mellings & Alden, 2000). Moreover, current evidence suggest that a 
large subset of individuals diagnosed with an anxiety disorder do not recover following 
evidence based psychological or pharmacological treatments (Blanco et al., 2003; Gould, 
Ott, & Pollack, 1995; Gould, Otto, Pollack, & Yap, 1997; Hofmann & Bögels, 2006), 
highlighting the need for new treatment strategies that enhance remission rates. A novel 
line of research has shown that treatment effects are augmented by pairing exposure 
therapy with a pharmacological agent (Hofmann, Fang, & Gutner, 2014; Otto, Behar, 
Smits, & Hofmann, 2009; Otto, Smits, & Reese, 2005; Singewald, Schmuckermair, 
Whittle, Holmes, & Ressler, 2015; Smits, Reese, Powers, & Otto, 2010). Given the present 
findings in women, combined with previous research showing that exogenous testosterone 
promotes social approach behavior in individuals with social anxiety disorder (Enter, 
Spinhoven, et al., 2016), it would be interesting for future investigations to explore whether 
the addition of testosterone as a pharmacological enhancer may augment the efficacy of 
exposure therapy in anxiety disorders. 
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In conclusion, the present findings demonstrate sex-dependent anxiolytic effects of 
testosterone in response to a psychological stressor. Taken together, these findings 
contribute to a better understanding of potential mechanisms associated with the 
development and maintenance of anxiety symptoms, and may help inform more efficacious 
treatments.
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Chapter 4: Effects of Exogenous Testosterone on Cognitive 
Performance 
ABSTRACT 
Can a single-dose of exogenous testosterone improve cognitive performance by 
reducing subjective anxiety? The present study extended findings from Study 2, and 
examined the effect of 14 mg intranasal testosterone on acute subjective anxiety and 
performance on the quantitative section of the Graduate Record Exam (GRE-Q) in a large, 
randomized, placebo-controlled trial (N = 150, 100% female). Participants completed pre-
drug administration trait anxiety measures, and rated their acute subjective anxiety using 
visual analogue scales before and after the GRE-Q. Results revealed a statistically 
significant anxiolytic effect of exogenous testosterone relative to placebo. Moreover, this 
drug effect was moderated by math anxiety, such that exogenous testosterone exerted the 
greatest anxiolytic effects for participants with highest levels of pre-drug administration 
math anxiety. No difference in GRE-Q performance was found between drug conditions. 
Instead, GRE-Q performance was predicted by correlates of general intelligence, including 
quantitative SAT performance, and verbal intelligence.  
BACKGROUND 
Test anxiety is one of the most pervasive academic impediments among students 
worldwide (Lowe & Ang, 2012). It describes a cluster of symptoms characterized by 
heightened anxiety before and/or during the taking of a test (Sarason, 1980) and has been 
associated with significant barriers to learning and performance (Andrews & Wilding, 
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2004). Compared with their low anxiety peers, highly test-anxious students score about 12 
percentiles below on standardized testing (Cassady & Johnson, 2002; R. Hembree, 1988; 
McDonald, 2001), and are significantly more likely to drop out of school (Andrews & 
Wilding, 2004; Pritchard & Wilson, 2003; Vaez & Laflamme, 2008). Not surprisingly, test 
anxiety can have broad negative impacts on general well-being and life satisfaction. A 
greater understanding of the etiology of test anxiety is warranted, and may lead to the 
development of better and more efficacious treatment for what is currently seen as an 
insidious and difficult-to-treat anxiety disorder. 
Research on the neuroendocrine basis of anxiety disorders in humans has linked 
testosterone to reductions in subjective anxiety (Study 2), and anxiety related behaviors 
(Enter et al., 2014; Enter, Spinhoven, et al., 2016; Enter, Terburg, et al., 2016; Hermans et 
al., 2006; van Honk et al., 2005). Presently, it is unknown whether testosterone 
administration will affect test performance. The present study aims to replicate and extend 
the findings from Study 2 by investigating the effect of testosterone administration on 
subjective anxiety and standardized test performance (using a quantitative section of the 
Graduate Record Examination, GRE-Q). It is hypothesized that testosterone administration 
will reduce subjective anxiety, and in turn, mediate improvements in GRE-Q performance. 
A secondary hypothesis is that trait test anxiety will moderate the effect of testosterone 
administration, such that the largest effects of testosterone administration will appear in 




A between-subjects, randomized, placebo-controlled research design was used to 
test the effect of single-dose, intranasal testosterone administration on GRE-Q 
performance. In addition to baseline trait measures (i.e., test anxiety, math anxiety, trait 
anxiety, and anxiety sensitivity), acute subjective anxiety was assessed before and after the 
GRE-Q using visual analogue scales. All procedures involving human participants have 
been approved and are in accordance with the ethical standards of The University of Texas 
at Austin Institutional Review Board (#IRB 2016-11-0049). 
Participants 
Power Analysis 
Based on medium to large effect sizes seen in previous testosterone administration 
studies in humans (e.g., Bos et al., 2013; Hermans et al., 2006, 2008; van Honk et al., 
2004), the present study was conservatively powered to detect a medium effect size. Power 
analyses using G*Power 3 (Faul et al., 2007), with alpha set to .05 indicated that a sample 
size of 110 participants will have greater than .80 power to detect a medium effect (f = .3) 
between conditions. 
Descriptive Statistics 
One hundred and fifty female participants registered in an introductory psychology 
class from The University of Texas at Austin enrolled in the study for course credit. Eligible 
participants were English-speaking adults between ages 18 and 30, with body mass index 
(BMI) between 17 kg/m2 and 35 kg/m2. Only female participants were recruited for this 
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study due to prior research (Study 2) demonstrating an anxiolytic effect of exogenous 
testosterone in women, but not in men. Participants were excluded if they had history of 
psychological or physical illness, or medication use that would impact endocrine 
functioning or preclude testosterone administration (e.g., breast/ovarian cancer, diabetes, 
thyroid disease). In addition, participants with daily recreational drug use (including, but 
not limited to, nicotine and alcohol), were excluded from participation. Participants 
currently using hormonal birth control, or experiencing irregular periods were also 
excluded from participation.  
The sample was approximately one-quarter Hispanic or Latino (25.7%), one-
quarter Asian (26.3%), and one-third White (34.9%), with mean age of 18.93 ± .99 years 
and BMI of 22.52 ± 2.96 kg/m2. Most participants were born in the United States (82.2%) 
and nearly half (46.7%) spoke language(s) other than English (see Table 3 for demographic 
characteristics by group). All participants provided written informed consent in accordance 




Table 3. Descriptive Statistics of Participants from Study 3 by Group 
 Placebo  Testosterone 
 (n = 75)  (n = 75) 
 M / % (SD) / (n)  M / % (SD) / (n) 
Demographics      
Age (years) 19.0 (1.1)  18.9 (0.9) 
BMI (kg/m2) 22.4 (3.1)  22.6 (2.8) 
Ethnicity (Hispanic or Latino) 25.3% (19)  25.3% (19) 
Race      
White 37.3% (28)  33.3% (25) 
Black or African American 8.0% (6)  14.7% (11) 
Asian 22.7% (17)  25.3% (19) 
Other 6.7% (5)  1.3% (1) 
Born in the US (Yes) 80.0% (60)  86.6% (65) 
Speak language(s) other than 
English (Yes) 49.3% (37)  58.7% (44) 
Baseline Measures      
Test Anxiety (CTAS) 45.3 (13.8)  41.1 (12.8) 
Math Anxiety (AMAS) 23.0 (6.4)  21.5 (7.3) 
Trait Anxiety (BAI) 9.4 (9.0)  7.8 (7.9) 
Anxiety Sensitivity (ASI-3) 15.0 (10.8)  13.3 (10.2) 
Baseline Subjective Anxiety (VAS) 2.2 (2.2)  2.4 (2.1) 
Note. M = mean, SD = standard deviation. Where appropriate, percentage (%) and 





All participants completed a demographic profile consisting of age, gender, 
ethnicity, high school grade point average (GPA), and SAT score, in addition to a series of 
study-specific questionnaires (test anxiety, math anxiety, trait anxiety, and anxiety 
sensitivity) prior to enrollment. Both the demographic profile and pre-enrollment 
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questionnaires were included as a part of the institution-approved pre-screen process 
associated with the online recruitment system used for research participation and entirely 
voluntary on the part of the participant. 
Scheduling 
Eligible participants were scheduled during the estimated mid-luteal phase of their 
menstrual cycles (between 17th and 24th day following the most recent onset of 
menstruation) in order to minimize the possible effects of cycling gonadal hormones on 
endocrine response (Kirschbaum et al., 1993; Viau, 2002). To assess cycle phase, 
participants were asked to recall the first day of their most recent menstruation during a 
telephone screening with a female research assistant. 
Intelligence Assessment 
To control for individual differences in intelligence, a brief assessment of 
intellectual functioning was administered prior to drug administration. The Wechsler Test 
of Adult Reading (WTAR) is a neuropsychological assessment tool used to provide a 
measure of intelligence by using vocabulary level as a correlate of general intelligence 
(Wechsler, 2001). All participants were presented with irregularly spelled words and 
prompted to pronounce each. The irregular grapheme-to-phoneme translations (such as the 
“gh” in the word tough) in the prompts make the word difficult to pronounce without 
having previously learned the word. Because participants cannot apply standard 
pronunciation rules to complete the task, the experimenter can assess participants’ 
vocabulary via their ability to pronounce the irregularly spelled words, and by extension, 
estimate their general intelligence (Wechsler, 2001). In standardized samples, WTAR 
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scores were shown to correlate highly with measures of verbal IQ (r = .75), verbal 
comprehension (r = .74), and full scale IQ (r = .73) (Strauss, Sherman, & Spreen, 2006). 
Pregnancy Test 
Following informed consent, all participants self-administered a urinary pregnancy 
test (Wondfo Pregnancy Strips, Willowbrook, IL) due to testosterone’s mutagenic effects 
on the fetus. Negative pregnancy status was verified prior to proceeding with drug 
administration. 
Testosterone Administration 
Participants were randomized to placebo or testosterone using a random sequence 
generated at randomizer.org. Only the study coordinator—who was neither involved in 
participant screening nor study administration—had access to the electronic list identifying 
each spray as containing testosterone or placebo, and its assigned participant. Both 
experimenters and participants were blind to the drug condition. All participants self-
administered an aqueous solution containing either 14 mg testosterone propionate or 
placebo, via intranasal spray (Figure 1). After self-administration of the nasal spray, 
participants were asked to relax for 30-minutes to allow testosterone levels to attain peak 
concentrations, based on the pharmacokinetic data from Study 1. Using the same protocol, 
dosage, and formulation as used here in Study 3, blood samples obtained via venipuncture 
in Study 1 showed peak levels for both free (bioavailable) and sex hormone-binding 
globulin (SHBG)-bound testosterone 30 minutes post-administration in women, which 
coincide with the start time of the GRE-Q (see below). 
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Graduate Record Examination Quantitative (GRE-Q) Battery 
30 minutes post drug administration, participants were instructed to complete 15 
quantitative questions from the Graduate Record Examination (GRE-Q) under time 
pressure (Clawson, Firment, & Trower, 1981; Reteguiz, 2006). Visual analogue scales 
(described below) assessing subjective anxiety were administered before and after the 
GRE-Q task. 
Measures 
Baseline Trait Measures 
The Cognitive Test Anxiety Scale (CTAS; Cassady & Johnson, 2002) is a 27-item 
self-report questionnaire designed to assess cognitive concerns associated with test taking. 
Respondents are asked to rate the extent to which the 27 items describe themselves using 
Likert scales (ranging from 0 or “not at all typical of me” to 4 or “very typical of me”). 
Example items include, “My mind goes blank when I am pressured for an answer on a test” 
and “I am a poor test taker in the sense that my performance on a test does not show how 
much I really know about a topic.” 
The Abbreviated Math Anxiety Scale (AMAS; Hopko, Mahadevan, Bare, & Hunt, 
2003) is a 9-item, self-report questionnaire designed to assess mathematics-related anxiety. 
Respondents are asked to rate the degree of anxiousness they experience in response to 
various situations (e.g., “Being given a ‘pop’ quiz in math class”) on a scale from 1 (“low 
anxiety”) to 5 (“high anxiety”). 
The Beck Anxiety Inventory (BAI; Beck et al., 1988) is a 21-item multiple choice 
(ranging from 0 to 3) self-report questionnaire designed to measure levels of anxious 
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symptomatology. The BAI assesses symptoms such as numbness and tingling, fear of 
losing control, and catastrophizing. 
The Anxiety Sensitivity Index-3 (ASI-3; Taylor et al., 2007) is an 18-item self-
report questionnaire designed to assess physical, cognitive, and social concerns associated 
with fear of arousal-related sensations. Respondents rate the extent to which the 18 items 
describe themselves using five-point Likert scales (ranging from 0 or “very little” to 4 or 
“very much”). 
Acute Subjective Anxiety 
A visual analogue scale was developed for the repeated assessment of acute state 
anxiety (Study 2). Participants were asked to report their anxiousness by indicating a 
position along a continuous, 10 cm line between two end-points: 0 for “not at all anxious” 
and 10 for “extremely anxious” in response to the prompt “Please indicate how anxious 
you are right now.” Data from each visual analogue scale was manually extracted using a 
metric ruler by a research assistant blind to drug condition. An example of the visual 
analogue scale is included as Figure 5. 
Data Analytic Plan 
Pre-Drug Administration Group Comparisons 
Independent samples t-tests were conducted to test for differences between the 
placebo and testosterone group in: intelligence (i.e., WTAR), prior academic performance 
(i.e., GPA, SAT-V, SAT-Q scores), baseline subjective anxiety (visual analogue scale), 
test-taking anxiety (CTAS), mathematics anxiety (AMAS), trait anxiety (BAI), and anxiety 
sensitivity (ASI-3). 
 71 
Predictors and Moderators of Subjective Anxiety and GRE-Q Performance 
Multiple linear regression models were used to test for main effect of drug 
condition, and moderators of drug effect including trait anxiety (BAI), test anxiety (CTAS), 
math anxiety (AMAS), and anxiety sensitivity (ASI-3) on subjective anxiety and GRE-Q 
performance, respectively. Significant two-way interactions between drug condition and 
moderators were further analyzed with simple slope analysis (Aiken, West, & Reno, 1991; 
J. F. Dawson & Richter, 2006). 
Condition Comparisons by Measurement Period 
Independent samples t-tests were conducted to test for drug condition differences 
in subjective anxiety at each of the three time points. 
Mediation of GRE-Q Performance 
A test of mediation (Baron & Kenny, 1986) was conducted to examine whether 
changes in subjective anxiety mediates any purported association between testosterone 
administration and GRE-Q performance. A series of simple regression analyses were 
conducted, including: (1) drug condition predicting GRE-Q performance, (2) drug 
condition predicting subjective anxiety, and (3) both drug condition and subjective anxiety 
predicting GRE-Q performance. 
RESULTS 
Pre-Drug Administration Group Comparisons 
No significant drug condition differences were found in any of the baseline, pre-
drug administration measures. Drug condition did not predict: general intelligence as 
measured by the Weschler Test of Adult Reading (t(149) = 0.861, p = 0.391, d = 0.140); 
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prior academic performance as indicated by high school GPA (t(144) = -0.048, p = 0.962, 
d = 0.008), verbal SAT score (t(150) = 0.665, p = 0.507, d = 0.108), or quantitative SAT 
score (t(150) = -0.024, p = 0.981, d = 0.004); baseline subjective anxiety as measured by 
visual analogue scale (t(141) = -0.353, p = 0.725, d = 0.059); trait anxiety as measured by 
the Cognitive Test Anxiety Scale (t(128) = 1.805, p = 0.073, d = 0.317), the Abbreviated 
Math Anxiety Scale (t(137) = 1.286, p = 0.201, d = 0.218), the Beck Anxiety Inventory 
(t(142) = 1.121, p = 0.264, d = 0.186), or the Anxiety Sensitivity Index (t(142) = 1.021, p 
= 0.309, d = 0.170). 
Predictors and Moderators of Subjective Anxiety and GRE-Q Performance 
Multiple linear regressions revealed a significant drug effect on changes in self-
reported anxiety (AUCI) as measured by repeated visual analogue scales (Mplacebo = 63.21, 
SD = 70.58; Mtestosterone = 38.37, SD = 52.52; β = -24.847, p = 0.018, d = 0.399; see Figure 
8 for summary data, and Figure 14 in the Appendix for individual participant plots). 
Moderation analyses further indicated that math anxiety (Abbreviated Math Anxiety Scale) 
significantly interacted with drug condition (β = -0.872, p = 0.004). Simple slope analysis 
of this significant interaction (Aiken et al., 1991; J. F. Dawson & Richter, 2006) suggested 
that exogenous testosterone had the largest effects on self-reported anxiety (AUCI) for 
participants with greatest trait math anxiety assessed pre drug-administration (β = -1.870, 
p = 0.002; Figure 9). 
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Figure 8. Subjective anxiety by drug condition across time 
 
Note. Error bars indicate standard error for each time point separately drug condition. 
Figure 9. Moderation of drug effect on subjective anxiety by math anxiety 
 
Note. High and low values are +1/-1 standard deviations around the mean. 
GRE-Q performance was not predicted by drug condition (β = -0.514, p = 0.258), 























































Cognitive Test Anxiety Scale (β = 0.078, p = 0.791), Abbreviated Math Anxiety Scale (β 
= -0.087, p = 0.777), and Anxiety Sensitivity (β = 0.258, p = 0.111)). 
Condition Comparisons by Measurement Period 
Subjective anxiety as measured by visual analogue scales did not differ across drug 
conditions during pre GRE-Q administration (t(140) = -0.165, p = 0.869, d = 0.028), post 
GRE-Q administration (t(142) = 1.298, p = 0.196, d = 0.216), or recovery (t(141) = 1.396, 
p = 0.165, d = 0.233). 
Mediation of GRE-Q Performance 
Mediation analysis revealed that changes in subjective anxiety across drug 
conditions did not impact GRE-Q performance (Figure 10). Specifically, a series of simple 
linear regressions showed that (1) drug condition did not significantly predict GRE-Q 
performance (β = -0.095, p = 0.258); (2) drug condition significantly predicted subjective 
anxiety (β = -0.197, p = 0.018); and (3) drug condition and subjective anxiety did not 
predict GRE-Q performance when both were entered into the regression model (p = 0.452). 




Considering that GRE-Q performance was not significantly predicted by drug 
condition, nor any trait anxiety measures (p > 0.05), a multiple linear regression was 
computed to identify significant predictor(s). Results indicated that GRE-Q performance 
was significantly predicted by SAT-quantitative (β = 0.811, p = 0.018), and Wechsler Test 
of Adult Reading—a brief estimate of general intelligence (β = 0.186, p = 0.040), Table 4. 
Table 4. Standardized Regression Coefficients Predicting GRE-Q Performance 
 B SE β 
(constant) -1.865 3.257 – 
Trait Anxiety (BAI) .051 .041 .147 
Anxiety Sensitivity (ASI-3) -.064 .032 -.249 
Math Anxiety (AMAS) .009 .040 .023 
Test Anxiety (CTAS) -.033 .021 -.159 
High School GPA 1.377 .794 .149 
SAT Verbal -.005 .003 -.501 
SAT Quantitative .008 .003 .811* 
IQ (WTAR) .029 .014 .186* 
*p<.05, **p<0.01, ***p<0.001 
 
Moreover, there was a trending, non-significant association between changes in 
acute self-reported anxiety (AUCI) and trait anxious symptomatology (BAI) when 
controlling for other trait anxiety measures and previous achievement testing and scholastic 
performance (p = .059), Table 5. 
  
 76 
Table 5. Standardized Regression Coefficients Predicting Subjective Anxiety 
 B SE β 
(constant) 73.402 82.909 – 
Trait Anxiety (BAI) 1.981 1.038 .249~ 
Anxiety Sensitivity (ASI-3) -.192 .808 -.032 
Math Anxiety (AMAS) -.711 1.015 -.077 
Test Anxiety (CTAS) .753 .526 .158 
High School GPA -20.258 20.214 -.095 
SAT Verbal .071 .083 .320 
SAT Quantitative -.084 .081 -.382 
IQ (WTAR) .300 .360 .082 
~p<.06, *p<.05, **p<0.01, ***p<0.001 
 
Lastly, mediation analysis demonstrated that trait math anxiety did not explain 
differences in acute subjective anxiety across drug conditions. Specifically, a series of 
simple linear regressions showed that while (1) drug condition did significantly predict 
acute subjective anxiety (β = -0.197, p = 0.018); (2) drug condition did not predict trait 
math anxiety (β = -0.109, p = 0.201); and (3) drug condition and trait math anxiety did not 
predict acute subjective anxiety when both were entered into the regression model (p = 
0.481). 
DISCUSSION 
The present study examined the effect of 14 mg intranasal testosterone 
administration on subjective anxiety and cognitive performance (using a quantitative 
section of the Graduate Record Examination, GRE-Q). Results revealed a statistically 
significant anxiolytic effect of exogenous testosterone relative to placebo as assessed by 
self-reported, repeatedly-measured, visual analogue scales. Moreover, this drug effect 
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was moderated by math anxiety (Abbreviated Math Anxiety Scale), such that exogenous 
testosterone had a statistically significant impact on subjective anxiety for participants 
with highest levels of math anxiety pre-drug administration. Drug effect on self-reported 
anxiety was not moderated by any other measures (i.e., trait anxiety, test anxiety, or 
anxiety sensitivity). No difference in GRE-Q performance was found between 
testosterone and placebo conditions. Instead, GRE-Q performance was more accurately 
predicted by correlates of general intelligence, including quantitative SAT performance, 
and Wechsler Test of Adult Reading (WTAR).  
To date, this is the first study to demonstrate an anxiolytic effect of testosterone 
administration on self-reported measures in response to a stressor. In contrast, previous 
studies have only reported behavioral effects of exogenous testosterone. These include 
diminished preconscious selective attention to threatening stimuli (van Honk et al., 2005), 
reduced gaze avoidance in individuals with social anxiety disorder (Enter, Terburg, et al., 
2016), reduced fear-potentiated startle response (Hermans et al., 2006), and increased 
behavioral approach (Enter et al., 2014; Enter, Spinhoven, et al., 2016). Considering that 
clinical assessment and diagnosis of anxiety is typically accomplished via a patient’s 
subjective report of his or her anxiety, rather than laboratory-based behavioral assessments, 
the outcome of the present study provides a more clinically valid test of the putative effects 
of exogenous testosterone and has significant implications for intervention. For example, 
lower academic anxiety was associated with higher liking and valuing of school, and 
greater academic motivation (Gottfried, 1985), particularly among children of lower social 
economic status (Dunn, 1968). Given that lower anxiety is associated with more behavioral 
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approach (Enter et al., 2014; Enter, Spinhoven, et al., 2016), individuals who are otherwise 
paralyzed by academic anxiety may experience less avoidance in response to scholastic 
stressors, and have additional opportunities to demonstrate mastery. 
Considering that the quantitative section of the Graduate Record Exam is composed 
exclusively of mathematical problem sets, it is not surprising that the drug effect on self-
reported anxiety was significantly moderated by math anxiety (Abbreviated Math Anxiety 
Scale). Contrary to study hypothesis, the drug effect was not moderated by more 
generalized test anxiety (i.e., Cognitive Test Anxiety Scale). This may be due to the broader 
specificity of test anxiety as a construct, relative to math anxiety. Replication of the present 
study using the verbal section of the GRE would be helpful in distinguishing the predictive 
power of the various moderators. 
Based on this set of findings, it appears that GRE-Q performance is not controlled 
by momentary changes or trait anxiety, but seems to be a reflection of g (a measure of 
general intelligence), similar to other scholastic admissions tests, such as the SAT. In 
fact, a correlation of .82 has been found between SAT scores and g scores computed from 
an IQ test battery (Frey & Detterman, 2004; Sackett, Borneman, & Connelly, 2008). Like 
other admission tests, the Graduate Record Exam was designed to assess different aspects 
of cognition, including verbal reasoning, quantitative reasoning, and critical thinking. 
Previous research suggests that other than significant alterations in brain health (e.g., 
atrophy or organic changes due to disease or toxin), no interventions have been shown to 
have long-term effects on measures associated with g (e.g., Heart Start Program, Neisser, 
1986). In fact, Kamphaus (2005) suggest that g accounts for 40 to 50 percent of the 
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between-individual performance differences on a given cognitive test. In light of these 
considerations, it is not surprising that drug administration did not yield a significant 
effect on GRE-Q performance. For future extension of the present findings, it would be 
important to include tasks that are less correlated or informed by g. For example, working 
memory tasks like Digit Span or Letter-Number Sequencing from the Wechsler Adult 
Intelligence Scale battery. Previous research indicates that individuals are more likely to 
allocate working memory resources to threat-related information (e.g., possibility of 
failure in the context of test anxiety), and thus have trouble with both encoding and recall 
(Ashcraft & Kirk, 2001; Ashcraft & Krause, 2007; Ikeda, Iwanaga, & Seiwa, 1996; 
Shackman et al., 2006; Stout, Shackman, Pedersen, Miskovich, & Larson, 2017). It is 
hypothesized that individuals randomized to the placebo condition will have worse 
performance on working memory tasks than those randomized to the testosterone 
condition due to greater resources allocated to test anxiety. 
Although this study utilized a female-only sample, it is worth noting possible 
effects of testosterone administration on subjective anxiety in males. Only a handful of 
studies have examined the effect of exogenous testosterone on self-reported mood 
outcomes in young, healthy, eugonadal men. Pope, Kouri, and Hudson (2000) found that 
600 mg of weekly testosterone administration led to increased ratings of manic symptoms 
in men. The authors cautioned that this effect was not uniform across individuals. 
Specifically, whereas a few developed prominent effects, most participants showed little 
psychological change (Pope et al., 2000). Similarly, Bhasin et al. (2001) did not detect 
differences in mood in a sample of healthy young men randomized to various dosages of 
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testosterone administration (0, 25, 50, 125, 300, 600 mg) over the course of 20 weeks. 
Lastly, no differences in subjective anxiety were detected between male participants 
randomized to placebo and testosterone conditions in Study 2. Based on these findings, it 
is theorized that the effect of testosterone administration on self-reported anxiety in 
women will likely not extend to men.  
In conclusion, the present study demonstrates an anxiolytic effect of testosterone 
on self-reported anxiety in a large female sample. Taken together, these findings contribute 
to a better understanding of potential mechanisms associated with the development and 





Chapter 5: General Discussion 
This dissertation examined the effects of a novel intranasal testosterone spray on 
physiological, psychological, and cognitive outcomes across three studies. Taken together, 
findings are consistent with greater literature on the anxiolytic effects of testosterone in 
humans and animals.  
Study 1 provided the methodological foundation for Studies 2 and 3 by establishing 
the utility, effectiveness, and pharmacokinetic profile of a novel intranasal testosterone 
spray in healthy men and women. Results from 23 participants (35% female) indicated that 
total and free testosterone concentrations increased in a linear fashion at 15- and 30-
minutes post testosterone administration, peaking at 30 minutes, and declining 60 minutes 
following administration. Study 2 leveraged the utility of this novel spray preparation, and 
investigated the effect of intranasal testosterone on stress-evoked (Trier Social Stress Test) 
subjective anxiety in a double-blind, placebo-controlled trial. Results from 104 participants 
(48.1% female) revealed a statistically significant drug by sex interaction, in which 
women—as expected—experienced significantly higher levels of subjective anxiety in the 
placebo condition compared to men; a sex difference that was eliminated in the drug 
condition. Further, women randomized to the testosterone condition experienced 
significantly lower levels of recovery (but not overall) anxiety from the Trier Social Stress 
Test relatively to women in the placebo condition. Study 3 extended the anxiolytic effects 
of testosterone in women from Study 2, and assessed the effect of intranasal testosterone 





female-only sample (N = 150). Results revealed a statistically significant anxiolytic effect 
of intranasal testosterone relative to placebo. Moreover, this drug effect was moderated by 
trait anxiety, such that exogenous testosterone exerted the greatest anxiolytic effects for 
participants with highest levels of pre-drug administration math anxiety. No difference in 
quantitative GRE performance was found between drug conditions. Instead, quantitative 
GRE performance was predicted by correlates of general intelligence, including 
quantitative SAT performance, and verbal intelligence. 
While the anxiolytic effect of testosterone was limited to the recovery period in 
Study 2, it generalized across the study when the female sample size was increased by 
approximately 188% (from N of 52 to 150) in Study 3. It seems that one possible 
explanation for the lack of elicit self-reported effects of exogenous testosterone in previous 
studies (O’Connor, Archer, Hair, & Wu, 2002; Terburg, Aarts, & van Honk, 2012; Adriaan 
Tuiten et al., 2002; van Honk et al., 2005) may be due to limited power associated with 
small samples sizes. Moreover, the nature of the Trier Social Stress Test may have made 
detecting subjective differences difficult. The large floor effects across visual analogue 
scales might have obscured the effect in this small sample study. In fact, meta-analysis of 
recovery findings from Study 1 and overall findings from Study 2 demonstrated a 
significant mean effect between placebo and testosterone conditions (z = -1.632, p = .021). 
POSSIBLE UNDERLYING NEUROBIOLOGICAL MECHANISMS 
Human neuroimaging studies suggest that the anxiolytic effects of testosterone may 





regions (e.g., amygdala), particularly in the modulation of approach and avoidance 
behaviors (Volman et al., 2011). In a sample of age matched male participants, a negative 
feedback loop is observed between orbitofrontal cortex and amygdala in healthy controls, 
compared to a positive, excitatory connection in patients with social anxiety (Sladky et al., 
2015).  
Exogenous testosterone studies in healthy females show that testosterone 
administration rapidly reduces functional coupling of the amygdala with the orbitofrontal 
cortex, and enhanced amygdala coupling with the thalamus (van Wingen et al., 2010) 
Specifically, this decoupling decreases behavioral inhibition and emotional rumination by 
either inhibiting signals from the amygdala to the orbitofrontal cortex, or redirecting those 
signals away from the orbitofrontal cortex (van Wingen et al., 2011). It has been suggested 
that the mechanism underlying this effect is likely a function of one or more of 
testosterone’s metabolites (van Wingen et al., 2010). For example, testosterone exerts a 
variety of downstream effects via its aromatization to estradiol. The enzyme aromatase—
responsible for metabolizing testosterone into estradiol in the brain—is capable of rapid 
aromatization of testosterone due to its proximity to the presynaptic terminals, resulting in 
behavioral changes within minutes of the onset of fluctuations in circulating testosterone 
levels (Balthazart & Ball, 2006).  
TRANSLATIONAL IMPLICATIONS 
Current evidence suggest that a large subset of individuals diagnosed with an 





pharmacological treatments (Blanco et al., 2003; Gould et al., 1995, 1997; Hofmann & 
Bögels, 2006), highlighting the need for new treatment strategies that enhance remission 
rates. A novel line of research has shown that treatment effects are augmented by pairing 
exposure therapy with a pharmacological agent (Hofmann et al., 2014; Otto et al., 2009, 
2005; Singewald et al., 2015; Smits et al., 2010). Given the present findings in women, 
combined with previous research showing that exogenous testosterone promotes social 
approach behavior in individuals with social anxiety disorder (Enter, Spinhoven, et al., 
2016), it would be interesting for future investigations to explore whether the addition of 
testosterone as a pharmacological enhancer may augment the efficacy of exposure therapy 
in anxiety disorders.  
In particular, the addition of testosterone administration may reduce the amount of 
time it takes for individuals to tackle items of higher intensity on their fear hierarchies in 
exposure therapy. Early success in exposure therapy has been shown to increase confidence 
and motivation, and a foster greater sense of mastery (E. A. Hembree & Cahill, 2007). Over 
time, smaller doses of testosterone nasal spray may be used to achieve similar anxiolytic 
effects, until no exogenous testosterone is needed. 
Unlike benzodiazepines or beta-blockers such as propranolol, both typically 
prescribed for the treatment of acute anxiety, testosterone does not exert depressant effects 
on the central nervous system, eliminating acute cognitive impairment, and potentially 






As with any study, the present findings must be interpreted in light of study 
limitations. First, all three studies were conducted using convenience samples consisting 
of participants relatively similar in terms of age, body mass, and gonadal status. Replication 
of findings using heterogeneous samples is needed. Second, the intranasal administration 
of testosterone resulted in post-nasal drip, which prohibited salivary testosterone samples 
from being effectively assayed due to contamination, and therefore no salivary data is 
available. Third, menstrual cycle phase for female participants were collected via self-
report. Future replications would benefit from more rigorous assessment of female 
participants’ hormonal status.  
FUTURE DIRECTIONS 
The present research examined the effect of intranasal testosterone on 
physiological, psychological, and cognitive outcomes; it does not however, address how 
testosterone exerts its influence. Existing neuroimaging studies (e.g., van Wingen et al., 
2010) point to possible causal mechanisms underlying its anxiolytic effects (e.g., Sladky 
et al., 2015; Volman et al., 2011). Future clinical neuroendocrinological research should 
incorporate methods from various fields to create a more complete picture of the 
mechanism and effect of intranasal testosterone in humans. For example, radioactive 
tracers used in positron emission tomography (PET) studies can help track the pathway of 





Another avenue for future research is the search for moderators, including 
evaluation of family history and genotyping for specific genetic profiles associated with 
anxiety disorders. Moreover, replications of the present research with high-risk samples, 
such as in individuals with remitted anxiety disorders will help to generalize the current 
research findings to more ecologically valid populations. 
Relatedly, it would be helpful to examine individual differences in enzyme 
metabolization in future replications of the present set of studies. For example, individual 
differences in the expression of aromatase, an enzyme catalyst involved the conversion of 
testosterone to estradiol (an estrogen) may explain variability in the efficacy of testosterone 
administration in women. It is hypothesized that women with higher levels of aromatase 
will experience greater anxiolytic effects of testosterone due to greater conversation to 
estradiol. Several existing studies have demonstrated both endogenous and exogenous 
aromatase in prolonging the effects testosterone in humans (Cherrier et al., 2005; Nathan 
et al., 2001). 
Finally, both Studies 2 and 3 examined the effect of exogenous testosterone using 
a between-subjects design. Given that anxiety is future-oriented, it would be helpful to 
explore the effect of intranasal testosterone on performance and willingness to approach 






Collectively, these three studies aim to contribute to a broader understanding of the 
anxiolytic effects of testosterone, and with it, the potential for testosterone to act as a novel 
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